{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:48:19Z","timestamp":1785894499621,"version":"3.56.0"},"reference-count":349,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"DOI":"10.1007\/s11011-025-01781-w","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:34:51Z","timestamp":1775547291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Peptide-based therapeutics in the management of Alzheimer\u2019s disease (AD) and their potential to develop novel strategies"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9091-7696","authenticated-orcid":false,"given":"Showkat Ul","family":"Nabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8452-4212","authenticated-orcid":false,"given":"Iyman","family":"Rasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6125-3309","authenticated-orcid":false,"given":"Andleeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7960-2594","authenticated-orcid":false,"given":"Abrar Ul","family":"Haq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2319-0965","authenticated-orcid":false,"given":"Iqra","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4430-2647","authenticated-orcid":false,"given":"Mosin Saleem","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3678-3313","authenticated-orcid":false,"given":"Sabhiya","family":"Majid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7692-6059","authenticated-orcid":false,"given":"Summya","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9987-5293","authenticated-orcid":false,"given":"Shahzada Mudasir","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7805-5058","authenticated-orcid":false,"given":"Nouroz","family":"Sehar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3627-5538","authenticated-orcid":false,"given":"Mashoque Ahmad","family":"Rather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9995-6576","authenticated-orcid":false,"given":"Muneeb U.","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"issue":"6","key":"1781_CR1","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2174\/138161212799277752","volume":"18","author":"S Aileen Funke","year":"2012","unstructured":"Aileen Funke S, Willbold D (2012) Peptides for therapy and diagnosis of Alzheimer\u2019s disease. Curr Pharm Des 18(6):755\u2013767","journal-title":"Curr Pharm Des"},{"key":"1781_CR2","doi-asserted-by":"crossref","unstructured":"Aggidis A, Devitt G, Zhang Y, Chatterjee S, Townsend D, Fullwood NJ, Ortega ER, Tarutani A, Hasegawa M, Cooper A, Williamson P, Mendoza-Oliva A, Diamond MI, Mudher A, Allsop D. A novel peptide-based tau aggregation inhibitor as a potential therapeutic for Alzheimer's disease and other tauopathies. Alzheimers Dement. 2024 Nov;20(11):7788-7804","DOI":"10.1002\/alz.14246"},{"key":"1781_CR3","unstructured":"Aisenbrey C, Borowik T, Bystr\u00f6m R, Bokvist M, Lindstr\u00f6m F, Misiak H, Sani MA, Gr\u00f6bner G (2020) How is protein aggregation in amyloidogenic diseases modulated by biological membranes? Biochim Biophys Acta Biomembr 1862(2):183\u2013208."},{"issue":"4","key":"1781_CR4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1042\/BST0370692","volume":"37","author":"H Amijee","year":"2009","unstructured":"Amijee H, Madine J, Middleton DA, Doig AJ (2009) Inhibitors of protein aggregation and toxicity. Biochem Soc Trans 37(4):692\u2013696","journal-title":"Biochem Soc Trans"},{"issue":"42","key":"1781_CR5","doi-asserted-by":"publisher","first-page":"8338","DOI":"10.1021\/bi300415v","volume":"51","author":"H Amijee","year":"2012","unstructured":"Amijee H, Bate C, Williams A, Virdee J, Jeggo R, Spanswick D, Scopes DI, Treherne JM, Mazzitelli S, Chawner R, Eyers CE (2012) The N-methylated peptide SEN304 powerfully inhibits A\u03b2 (1\u201342) toxicity by perturbing oligomer formation. Biochemistry 51(42):8338\u20138352","journal-title":"Biochemistry"},{"issue":"31","key":"1781_CR6","doi-asserted-by":"publisher","first-page":"8236","DOI":"10.1002\/anie.201405109","volume":"53","author":"T Arai","year":"2014","unstructured":"Arai T, Araya T, Sasaki D, Taniguchi A, Sato T, Sohma Y, Kanai M (2014) Rational design and identification of a non-peptidic aggregation inhibitor of amyloid-\u03b2 based on a pharmacophore motif obtained from cyclo [-Lys-Leu-Val-Phe-Phe-]. Angew Chem Int Ed Engl 53(31):8236\u20138239","journal-title":"Angew Chem Int Ed Engl"},{"issue":"7","key":"1781_CR7","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1021\/bi701415b","volume":"47","author":"BM Austen","year":"2008","unstructured":"Austen BM, Paleologou KE, Ali SA, Qureshi MM, Allsop D, El-Agnaf OM (2008a) Designing peptide inhibitors for oligomerization and toxicity of Alzheimer\u2019s \u03b2-amyloid peptide. Biochemistry 47(7):1984\u20131992","journal-title":"Biochemistry"},{"issue":"7","key":"1781_CR8","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1021\/bi701415b","volume":"247","author":"BM Austen","year":"2008","unstructured":"Austen BM, Paleologou KE, Ali SA, Qureshi MM, Allsop D, El-Agnaf OM (2008b) Designing peptide inhibitors for oligomerization and toxicity of Alzheimer\u2019s \u03b2-amyloid peptide. Biochemistry 247(7):1984\u20131992","journal-title":"Biochemistry"},{"key":"1781_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2017.00058","volume":"8","author":"EP Barykin","year":"2017","unstructured":"Barykin EP, Mitkevich VA, Kozin SA, Makarov AA (2017) Amyloid \u03b2 modification: a key to the sporadic Alzheimer\u2019s disease? Front Genet 8:58","journal-title":"Front Genet"},{"key":"1781_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080771","volume":"8","author":"EP Barykin","year":"2019","unstructured":"Barykin EP, Garifulina AI, Kruykova EV, Spirova EN, Anashkina AA, Adzhubei AA, Shelukhina IV, Kasheverov IE, Mitkevich VA et al (2019) Isomerization of Asp7 in beta-amyloid enhances inhibition of the \u03b17 nicotinic receptor and promotes neurotoxicity. Cells 8:771","journal-title":"Cells"},{"key":"1781_CR11","doi-asserted-by":"publisher","first-page":"6272","DOI":"10.3390\/ijms21176272","volume":"21","author":"EP Barykin","year":"2020","unstructured":"Barykin EP, Garifulina AI, Tolstova AP, Anashkina AA, Adzhubei AA, Mezentsev YV, Shelukhina IV, Kozin SA, Tsetlin VI et al (2020) Tetrapeptide Ac-HAEE-NH2 protects \u03b14\u03b22 nAChR from inhibition by A\u03b2. Int J Mol Sci 21:6272","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1781_CR12","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.psyneuen.2004.04.003","volume":"29","author":"C Benedict","year":"2004","unstructured":"Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W (2004) Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29(10):1326\u20131334","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"1781_CR13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/sj.npp.1301193","volume":"32","author":"C Benedict","year":"2007","unstructured":"Benedict C, Hallschmid M, Schmitz K, Schultes B, Ratter F, Fehm HL, Born J, Kern W (2007) Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 32(1):239\u2013243","journal-title":"Neuropsychopharmacology"},{"key":"1781_CR14","doi-asserted-by":"crossref","unstructured":"Benedict C, Hallschmid M, Schultes B, Born J, Kern W (2006) Intranasal insulin improves memory in humans. Neurobiol Aging 25(1):1326\u20131332.","DOI":"10.1055\/s-2006-943764"},{"issue":"4","key":"1781_CR15","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1210\/jc.2007-2606","volume":"93","author":"C Benedict","year":"2008","unstructured":"Benedict C, Kern W, Schultes B, Born J, Hallschmid M (2008) Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metab 93(4):1339\u20131344","journal-title":"J Clin Endocrinol Metab"},{"key":"1781_CR16","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nrn2494","volume":"9","author":"L Bertram","year":"2008","unstructured":"Bertram L, Tanzi RE (2008) Thirty years of Alzheimer\u2019s disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 9:768\u2013778","journal-title":"Nat Rev Neurosci"},{"key":"1781_CR18","unstructured":"Bhat SA, Goel R, Shukla R, Hanif K (2018) Angiotensin receptor blockers in Alzheimer\u2019s disease. Neurosci Biobehav Rev 85:1\u20139."},{"issue":"1","key":"1781_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ajpath.2015.09.018","volume":"186","author":"T Bilousova","year":"2016","unstructured":"Bilousova T, Miller CA, Poon WW, Vinters HV, Corrada M, Kawas C, Hayden EY, Teplow DB, Glabe C, Albay R III, Cole GM (2016) Synaptic amyloid-\u03b2 oligomers precede p-tau and differentiate high pathology control cases. Am J Pathol 186(1):185\u2013198","journal-title":"Am J Pathol"},{"issue":"5","key":"1781_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1159\/000358875","volume":"60","author":"A Boutajangout","year":"2014","unstructured":"Boutajangout A, Wisniewski T (2014) Tau-based therapeutic approaches for Alzheimer\u2019s disease-a mini-review. Gerontology 60(5):381\u2013385","journal-title":"Gerontology"},{"issue":"3","key":"1781_CR21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"R Brookmeyer","year":"2007","unstructured":"Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer\u2019s disease. Alzheimers Dement 3(3):186\u2013191","journal-title":"Alzheimers Dement"},{"key":"1781_CR22","doi-asserted-by":"crossref","unstructured":"Brunden KR, Trojanowski JQ, Lee VM (2013) Advances in tau-targeted therapeutics. Nat Rev Drug Discov 8(10):783\u2013793.","DOI":"10.1038\/nrd2959"},{"issue":"41","key":"1781_CR23","doi-asserted-by":"publisher","first-page":"13861","DOI":"10.1523\/JNEUROSCI.3059-10.2010","volume":"30","author":"KR Brunden","year":"2010","unstructured":"Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, Iba M, James MJ, Xie SX, Ballatore C, Smith AB (2010) Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy. J Neurosci 30(41):13861\u201313866","journal-title":"J Neurosci"},{"issue":"7s_part_12","key":"1781_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jalz.2017.07.241","volume":"13","author":"K Budur","year":"2017","unstructured":"Budur K, West T, Braunstein JB, Fogelman I, Bordelon YM, Litvan I, Roberson ED, Hu H, Verghese PB, Bateman RJ, Florian H (2017) Results of a phase 1, single ascending dose, placebo-controlled study of abbv-8e12 in patients with progressive supranuclear palsy and phase 2 study design in early alzheimer\u2019s disease. Alzheimer Dement 13(7s_part_12):599\u2013600","journal-title":"Alzheimer Dement"},{"issue":"2","key":"1781_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/biom13020313","volume":"13","author":"W Cai","year":"2023","unstructured":"Cai W, Wu T, Chen N (2023) The amyloid-beta clearance: from molecular targets to glial and neural cells. Biomolecules 13(2):313","journal-title":"Biomolecules"},{"key":"1781_CR27","doi-asserted-by":"publisher","DOI":"10.36838\/v7i4.5","author":"N Chen","year":"2025","unstructured":"Chen N (2025) Ml-driven approach to discovery of peptide-based BACE1 inhibitors. Int J High School Res. https:\/\/doi.org\/10.36838\/v7i4.5","journal-title":"Int J High School Res"},{"key":"1781_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pneurobio.2013.06.004","volume":"108","author":"Z Chen","year":"2013","unstructured":"Chen Z, Zhong C (2013) Decoding Alzheimer\u2019s disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol 108:21\u201343","journal-title":"Prog Neurobiol"},{"issue":"9","key":"1781_CR29","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/aps.2017.28","volume":"38","author":"GF Chen","year":"2017","unstructured":"Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, Xu HE (2017a) Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 38(9):1205\u20131235","journal-title":"Acta Pharmacol Sin"},{"key":"1781_CR30","doi-asserted-by":"crossref","unstructured":"Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, Xu HE (2018) Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 38(9):1205\u20131235.","DOI":"10.1038\/aps.2017.28"},{"issue":"3","key":"1781_CR31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/jnc.14048","volume":"141","author":"W Chen","year":"2017","unstructured":"Chen W et al (2017b) Amyloid precursor protein processing and Alzheimer\u2019s disease. J Neurochem 141(3):297\u2013309","journal-title":"J Neurochem"},{"issue":"1","key":"1781_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt1273","volume":"25","author":"AC Cheng","year":"2007","unstructured":"Cheng AC, Coleman RG, Smyth KT, Cao Q, Soulard P, Caffrey DR, Salzberg AC, Huang ES (2007) Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 25(1):71\u201375","journal-title":"Nat Biotechnol"},{"issue":"5","key":"1781_CR33","doi-asserted-by":"publisher","first-page":"703","DOI":"10.15252\/emmm.201606666","volume":"9","author":"YS Cheng","year":"2017","unstructured":"Cheng YS, Chen ZT, Liao TY, Lin C, Shen HC, Wang YH, Chang CW, Liu RS, Chen RP, Tu PH (2017) An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice. EMBO Mol Med 9(5):703\u2013715","journal-title":"EMBO Mol Med"},{"key":"1781_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1630475","volume":"16","author":"N Chengebroyen","year":"2025","unstructured":"Chengebroyen N, Seelan A, Thajudeen KY, Alshehri S, Biswas A, Adur I, Sundararajan V, Lulu SS, Singh H (2025) Harnessing nanotechnology for stem-cell therapies: revolutionizing neurodegenerative disorder treatments\u2014a state-of-the-art update. Front Pharmacol 16:1630475","journal-title":"Front Pharmacol"},{"key":"1781_CR35","doi-asserted-by":"crossref","unstructured":"Chintamaneni PK, Pindiprolu SSS, Krishnamurthy PT, Varshni MS (2025) Targeted drug delivery: amyloid beta targeting drugs, immunotherapy, anti-tau and aggregation inhibitor, microtubule-stabilizing, and neuroinflammation modulation. In: Multi-Factorial Approach as a Therapeutic Strategy for the Management of Alzheimer\u2019s Disease. pp 237\u2013258","DOI":"10.1007\/978-981-96-0259-9_12"},{"issue":"10","key":"1781_CR36","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0167-7799(00)88999-4","volume":"13","author":"M Chorev","year":"1995","unstructured":"Chorev M, Goodman M (1995) Recent developments in retro peptides and proteins\u2014an ongoing topochemical exploration. Trends Biotechnol 13(10):438\u2013445","journal-title":"Trends Biotechnol"},{"issue":"11","key":"1781_CR37","doi-asserted-by":"publisher","first-page":"17080","DOI":"10.1021\/acsnano.1c03800","volume":"15","author":"V Chugh","year":"2021","unstructured":"Chugh V, Vijaya Krishna K, Pandit A (2021) Cell membrane-coated mimics: a methodological approach for fabrication, characterization for therapeutic applications, and challenges for clinical translation. ACS Nano 15(11):17080\u201317123","journal-title":"ACS Nano"},{"issue":"5","key":"1781_CR38","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nrd2896","volume":"9","author":"M Citron","year":"2010","unstructured":"Citron M (2010) Alzheimer\u2019s disease: strategies for disease modification. Nat Rev Drug Discov 9(5):387\u2013398","journal-title":"Nat Rev Drug Discov"},{"key":"1781_CR39","doi-asserted-by":"crossref","unstructured":"Clavaguera F, Bolmont T, Crowther RA, et al. (2009) Transmission of tau pathology. Nat Cell Biol 11(7):909\u2013913.","DOI":"10.1038\/ncb1901"},{"issue":"3","key":"1781_CR40","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3233\/JAD-141791","volume":"44","author":"A Claxton","year":"2015","unstructured":"Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S (2015) Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer\u2019s disease dementia. J Alzheimers Dis 44(3):897\u2013906","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"1781_CR41","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","volume":"69","author":"V Coric","year":"2012","unstructured":"Coric V, Van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S (2012) Safety and tolerability of the \u03b3-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69(11):1430\u20131440","journal-title":"Arch Neurol"},{"key":"1781_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.05.569","volume":"9","author":"V Coric","year":"2013","unstructured":"Coric V, Salloway S, van Dyck C, Kerselaers W, Kaplita S, Curtis C, Ross J, Richter RW, Andreasen N, Brody M, Sharma SK (2013) A phase II study of the gamma-secretase inhibitor avagacestat (BMS-708163) in predementia Alzheimer\u2019s disease. Alzheimer Dement 9:283","journal-title":"Alzheimer Dement"},{"issue":"1","key":"1781_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13311-016-0481-z","volume":"14","author":"SE Counts","year":"2017","unstructured":"Counts SE, Ikonomovic MD, Mercado N, Vega IE, Mufson EJ (2017) Biomarkers for the early detection and progression of Alzheimer\u2019s disease. Neurotherapeutics 14(1):35\u201353","journal-title":"Neurotherapeutics"},{"issue":"1","key":"1781_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archneurol.2011.233","volume":"69","author":"S Craft","year":"2012","unstructured":"Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69(1):29\u201338","journal-title":"Arch Neurol"},{"issue":"1","key":"1781_CR45","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/cbdd.12055","volume":"81","author":"DJ Craik","year":"2013","unstructured":"Craik DJ, Fairlie DP, Liras S, Price D (2013) The future of peptide-based drugs. Chem Biol Drug Des 81(1):136\u2013147","journal-title":"Chem Biol Drug Des"},{"issue":"3","key":"1781_CR46","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1399-3011.2004.00156.x","volume":"63","author":"M Cruz","year":"2004","unstructured":"Cruz M, Tusell JM, Grillo-Bosch D, Albericio F, Serratosa J, Rabanal F, Giralt E (2004) Inhibition of \u03b2-amyloid toxicity by short peptides containing N-methyl amino acids. J Pept Res 63(3):324\u2013328","journal-title":"J Pept Res"},{"key":"1781_CR47","unstructured":"D\u2019Aloisio V (2022) Design, synthesis, and evaluation of serum-stable peptide antagonists of the CGRP receptor as a novel treatment for migraine. PhD Thesis, Liverpool John Moores University (United Kingdom)"},{"issue":"18","key":"1781_CR48","doi-asserted-by":"publisher","first-page":"7395","DOI":"10.1074\/jbc.M116.753525","volume":"292","author":"GS da Silva","year":"2017","unstructured":"da Silva GS, Melo HM, Lourenco MV, e Silva NM, De Carvalho MB, Alves-Leon SV, De Souza JM, Klein WL, Da-Silva WS, Ferreira ST, De Felice FG (2017) Amyloid-\u03b2 oligomers transiently inhibit AMP-activated kinase and cause metabolic defects in hippocampal neurons. J Biol Chem 292(18):7395\u2013406","journal-title":"J Biol Chem"},{"key":"1781_CR49","doi-asserted-by":"crossref","unstructured":"Danho W, Swistok J, Khan W, Chu XJ, Cheung A, Fry D, Sun H, Kurylko G, Rumennik L, Cefalu J, Cefalu G (2009) Opportunities and challenges of developing peptide drugs in the pharmaceutical industry. In: Peptides for Youth: The Proceedings of the 20th American Peptide Symposium Springer New York, pp 467\u2013469","DOI":"10.1007\/978-0-387-73657-0_201"},{"issue":"2","key":"1781_CR50","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.expneurol.2009.08.032","volume":"223","author":"KA DaSilva","year":"2010","unstructured":"DaSilva KA, Shaw JE, McLaurin J (2010) Amyloid-\u03b2 fibrillogenesis: structural insight and therapeutic intervention. Exp Neurol 223(2):311\u2013321","journal-title":"Exp Neurol"},{"key":"1781_CR51","unstructured":"De Felice FG, Ferreira ST (2005) Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer\u2019s disease. J Alzheimers Dis 7(4):285\u2013295."},{"issue":"6","key":"1781_CR52","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1073\/pnas.0809158106","volume":"106","author":"FG De Felice","year":"2009","unstructured":"De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP, Viola KL, Zhao WQ, Ferreira ST, Klein WL (2009) Protection of synapses against Alzheimer\u2019s-linked toxins: insulin signaling prevents the pathogenic binding of A\u03b2 oligomers. Proc Natl Acad Sci U S A 106(6):1971\u20131976","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1781_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6807-5-18","volume":"5","author":"NS De Groot","year":"2005","unstructured":"De Groot NS, Pallar\u00e9s I, Avil\u00e9s FX, Vendrell J, Ventura S (2005) Prediction of \u201chot spots\u201d of aggregation in disease-linked polypeptides. BMC Struct Biol 5(1):18","journal-title":"BMC Struct Biol"},{"issue":"7","key":"1781_CR54","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nm890","volume":"9","author":"R Deane","year":"2003","unstructured":"Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H (2003) Rage mediates amyloid-\u03b2 peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9(7):907\u2013913","journal-title":"Nat Med"},{"issue":"1","key":"1781_CR55","first-page":"16","volume":"8","author":"R Deane","year":"2009","unstructured":"Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clearance of amyloid-\u03b2 peptide across the blood-brain barrier: implication for therapies in Alzheimer\u2019s disease. CNS Neurol Disord-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders) 8(1):16\u201330","journal-title":"CNS Neurol Disord-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)"},{"key":"1781_CR56","doi-asserted-by":"crossref","unstructured":"DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, Chen G, Shen T, Tran H, Nichols B, Zanardi TA. (2017) Tau reduction prevents neuronal loss. Sci Transl Med 9(374): eaag0481.","DOI":"10.1126\/scitranslmed.aag0481"},{"key":"1781_CR57","unstructured":"Devkota S, Chang EB (2001) Interactions between diet, microbiota and Alzheimer\u2019s disease. Trends Mol Med 17(10):507\u2013515."},{"key":"1781_CR58","unstructured":"Doig AJ (2004) Peptide inhibitors of amyloid formation. Curr Opin Struct Biol 14(1):121\u2013127."},{"key":"1781_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100281","author":"S Devkota","year":"2021","unstructured":"Devkota S, Williams TD, Wolfe MS (2021) Familial Alzheimer\u2019s disease mutations in amyloid protein precursor alter proteolysis by \u03b3-secretase to increase amyloid \u03b2-peptides of\u2265 45 residues. J Biol Chem. https:\/\/doi.org\/10.1016\/j.jbc.2021.100281","journal-title":"J Biol Chem"},{"key":"1781_CR60","first-page":"533","volume":"10","author":"AJ Doig","year":"2007","unstructured":"Doig AJ (2007) Peptide inhibitors of b-amyloid aggregation. Curr Opin Drug Discov Devel 10:533\u2013539","journal-title":"Curr Opin Drug Discov Devel"},{"key":"1781_CR61","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.sbi.2014.12.004","volume":"30","author":"AJ Doig","year":"2015","unstructured":"Doig AJ, Derreumaux P (2015) Inhibition of protein aggregation and amyloid formation by small molecules. Curr Opin Struct Biol 30:50\u20136","journal-title":"Curr Opin Struct Biol"},{"issue":"4","key":"1781_CR62","first-page":"264","volume":"4","author":"R Doody","year":"2017","unstructured":"Doody R (2017) Developing disease-modifying treatments in Alzheimer\u2019s disease-a perspective from Roche and Genentech. J Prev Alzheimers Dis 4(4):264\u2013272","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"1781_CR63","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS (2013) A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med 369(4):341\u2013350","journal-title":"N Engl J Med"},{"key":"1781_CR65","doi-asserted-by":"crossref","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E. (2018) Phase 3 trials of solanezumab. N Engl J Med 370(4):311\u2013321.","DOI":"10.1056\/NEJMoa1312889"},{"issue":"7","key":"1781_CR66","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028035","volume":"9","author":"BN Dugger","year":"2017","unstructured":"Dugger BN, Dickson DW (2017) Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol 9(7):a028035","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1781_CR67","unstructured":"Eckert A, Schmitt K, G\u00f6tz J (2014) Mitochondrial dysfunction in Alzheimer\u2019s disease. Trends Neurosci 34(2):93\u2013102."},{"issue":"6","key":"1781_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066178","volume":"8","author":"G Eskici","year":"2013","unstructured":"Eskici G, Gur M (2013) Computational design of new peptide inhibitors for amyloid beta (A\u03b2) aggregation in Alzheimer\u2019s disease: application of a novel methodology. PLoS ONE 8(6):e66178","journal-title":"PLoS ONE"},{"issue":"1","key":"1781_CR69","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2174\/156802607779318262","volume":"7","author":"LD Estrada","year":"2007","unstructured":"Estrada LD, Soto C (2007) Disrupting \u03b2-amyloid aggregation for Alzheimer disease treatment. Curr Top Med Chem 7(1):115\u2013126","journal-title":"Curr Top Med Chem"},{"key":"1781_CR70","doi-asserted-by":"crossref","unstructured":"Estrada LD, Lasagna C, Soto C (2007) Design of inhibitors of amyloid-beta misfolding and aggregation for alzheimer\u2019s therapy. Pharmacological Mechanisms in Alzheimer\u2019s Therapeutics. Springer, New York, NY, USA, pp 238\u2013254","DOI":"10.1007\/978-0-387-71522-3_15"},{"issue":"2","key":"1781_CR71","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/157488911795933938","volume":"6","author":"G Evin","year":"2011","unstructured":"Evin G, Lessene G, Wilkins S (2011) Bace inhibitors as potential drugs for the treatment of Alzheimer\u2019s disease: focus on bioactivity. Recent Patents CNS Drug Discov 6(2):91\u2013106","journal-title":"Recent Patents CNS Drug Discov"},{"issue":"10","key":"1781_CR72","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrd3288","volume":"9","author":"A Extance","year":"2010","unstructured":"Extance A (2010) Alzheimer\u2019s failure raises questions about disease-modifying strategies. Nat Rev Drug Discov 9(10):749\u2013751","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"1781_CR73","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1021\/cr970468t","volume":"98","author":"MD Fletcher","year":"1998","unstructured":"Fletcher MD, Campbell MM (1998) Partially modified retro-inverso peptides: development, synthesis, and conformational behavior. Chem Rev 98(2):763\u2013796","journal-title":"Chem Rev"},{"issue":"1","key":"1781_CR74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.nrleng.2015.03.019","volume":"33","author":"J Folch","year":"2018","unstructured":"Folch J, Ettcheto M, Petrov D, Abad S, Pedr\u00f3s I, Marin M, Olloquequi J, Camins A (2018) Review of the advances in treatment for Alzheimer disease: strategies for combating \u03b2-amyloid protein. Neurolog\u00eda (English Edition) 33(1):47\u201358","journal-title":"Neurolog\u00eda (English Edition)"},{"key":"1781_CR75","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/jnc.14257","volume":"144","author":"KH Forest","year":"2018","unstructured":"Forest KH, Alfulaij N, Arora K, Taketa R, Sherrin T, Todorovic C, Lawrence JL, Yoshikawa GT, Ng HL et al (2018) Protection against \u03b2-amyloid neurotoxicity by a non-toxic endogenous N-terminal \u03b2-amyloid fragment and its active hexapeptide core sequence. J Neurochem 144:201\u2013217","journal-title":"J Neurochem"},{"issue":"8","key":"1781_CR76","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.bmc.2015.02.041","volume":"23","author":"A Francioso","year":"2015","unstructured":"Francioso A, Punzi P, Boffi A, Lori C, Martire S, Giordano C, D\u2019Erme M, Mosca L (2015Z) \u03b2-sheet interfering molecules acting against \u03b2-amyloid aggregation and fibrillogenesis. Bioorg Med Chem 23(8):1671\u20131683","journal-title":"Bioorg Med Chem"},{"issue":"14","key":"1781_CR77","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1097\/00001756-199909290-00017","volume":"10","author":"H Fukumoto","year":"1999","unstructured":"Fukumoto H, Tomita T, Matsunaga H, Ishibashi Y, Saido TC, Iwatsubo T (1999) Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid \u03b2 peptides ending at A\u03b240 and A\u03b242. Neuroreport 10(14):2965\u20132969","journal-title":"Neuroreport"},{"issue":"12","key":"1781_CR78","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1212\/WNL.60.12.1886","volume":"60","author":"D Galasko","year":"2003","unstructured":"Galasko D (2003) Insulin and Alzheimer\u2019s disease: an amyloid connection. Neurology 60(12):1886\u20131887","journal-title":"Neurology"},{"issue":"40","key":"1781_CR79","doi-asserted-by":"publisher","first-page":"15659","DOI":"10.1073\/pnas.0705888104","volume":"104","author":"AS Gardberg","year":"2007","unstructured":"Gardberg AS, Dice LT, Ou S, Rich RL, Helmbrecht E, Ko J, Wetzel R, Myszka DG, Patterson PH, Dealwis C (2007) Molecular basis for passive immunotherapy of Alzheimer\u2019s disease. Proc Natl Acad Sci U S A 104(40):15659\u201315664","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5697","key":"1781_CR80","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1126\/science.1101262","volume":"306","author":"JE Gestwicki","year":"2004","unstructured":"Gestwicki JE, Crabtree GR, Graef IA (2004) Harnessing chaperones to generate small-molecule inhibitors of amyloid \u00df aggregation. Science 306(5697):865\u2013869","journal-title":"Science"},{"issue":"15","key":"1781_CR81","doi-asserted-by":"publisher","first-page":"7246","DOI":"10.3390\/ijms26157246","volume":"26","author":"M Ghosh","year":"2025","unstructured":"Ghosh M, Bayat AH, Pearse DD (2025) Small extracellular vesicles in neurodegenerative disease: emerging roles in pathogenesis, biomarker discovery, and therapy. Int J Mol Sci 26(15):7246","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1781_CR82","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/1531-8249(200009)48:3<297::AID-ANA3>3.0.CO;2-Z","volume":"48","author":"GE Gibson","year":"2007","unstructured":"Gibson GE, Haroutunian V, Zhang H, Park LC, Shi Q, Lesser M, Mohs RC, Sheu RK, Blass JP (2007) Mitochondrial damage in Alzheimer\u2019s disease varies with apolipoprotein E genotype. Ann Neurol 48(3):297\u2013303","journal-title":"Ann Neurol"},{"key":"1781_CR83","unstructured":"Gibson GE, Huang HM. (2008) Oxidative stress in Alzheimer\u2019s disease. Free Radic Biol Med 45(11):1426\u20131438."},{"key":"1781_CR84","first-page":"497","volume-title":"Learning and memory: From brain to behavior","author":"MA Gluck","year":"2014","unstructured":"Gluck MA, Mercado E, Myers CE (2014) Learning and memory: From brain to behavior, 2nd edn. Worth Publishers, New York, NY, USA xxiii, p 497","edition":"2"},{"key":"1781_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00719-x","volume":"12","author":"K Gnoth","year":"2020","unstructured":"Gnoth K, Piechotta A, Kleinschmidt M, Konrath S, Schenk M, Taudte N, Ramsbeck D, Rieckmann V, Geissler S et al (2020) Targeting isoaspartate-modified A\u03b2 rescues behavioral deficits in transgenic mice with Alzheimer\u2019s disease-like pathology. Alzheimers Res Ther 12:149","journal-title":"Alzheimers Res Ther"},{"key":"1781_CR86","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/jnc.13583","volume":"139","author":"TE Golde","year":"2016","unstructured":"Golde TE (2016) Overcoming translational barriers impeding development of Alzheimer\u2019s disease modifying therapies. J Neurochem 139:224\u2013236","journal-title":"J Neurochem"},{"issue":"5","key":"1781_CR87","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/j.1476-5381.2011.01713.x","volume":"165","author":"J G\u00f6tz","year":"2012","unstructured":"G\u00f6tz J, Ittner A, Ittner LM (2012) Tau-targeted treatment strategies in Alzheimer\u2019s disease. Br J Pharmacol 165(5):1246\u20131259","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1781_CR88","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1021\/acscombsci.6b00116","volume":"19","author":"D Goyal","year":"2017","unstructured":"Goyal D, Shuaib S, Mann S, Goyal B (2017) Rationally designed peptides and peptidomimetics as inhibitors of amyloid-\u03b2 (A\u03b2) aggregation: potential therapeutics of Alzheimer\u2019s disease. ACS Comb Sci 19(2):55\u201380","journal-title":"ACS Comb Sci"},{"key":"1781_CR89","unstructured":"Gozes I, Ivashko-Pachima Y, Sayas CL (2017) Activity-dependent neuroprotective protein (ADNP). J Alzheimers Dis 56(4):1343\u20131353."},{"issue":"4","key":"1781_CR90","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1527-3458.2005.tb00053.x","volume":"11","author":"I Gozes","year":"2005","unstructured":"Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y (2005) NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev 11(4):353\u2013368","journal-title":"CNS Drug Rev"},{"issue":"23","key":"1781_CR91","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"RC Green","year":"2009","unstructured":"Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH (2009) Tarenflurbil phase 3 study group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. Jama 302(23):2557\u201364","journal-title":"Jama"},{"key":"1781_CR92","doi-asserted-by":"crossref","unstructured":"Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. (1986) Tau protein abnormalities in Alzheimer disease. Proc Natl Acad Sci USA 83(13):4913\u20134917.","DOI":"10.1073\/pnas.83.13.4913"},{"issue":"1","key":"1781_CR93","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12603-013-0002-2","volume":"17","author":"M Grundman","year":"2013","unstructured":"Grundman M, Dibernardo A, Raghavan N, Krams M, Yuen E (2013) 2012: a watershed year for Alzheimer\u2019s disease research. J Nutr Health Aging 17(1):51\u201353","journal-title":"J Nutr Health Aging"},{"key":"1781_CR94","doi-asserted-by":"crossref","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L. (2013) TREM2 variants in Alzheimer\u2019s disease. N Engl J Med 368(2):117\u2013127.","DOI":"10.1056\/NEJMoa1211851"},{"key":"1781_CR95","doi-asserted-by":"publisher","unstructured":"Guleria M, Malhan A, Teli G, Bisht N, Jain SK (2025) Design strategies, structural insights, and biological potential of amyloid-beta inhibitors in Alzheimer\u2019s disease. Mol Divers 1\u201326. https:\/\/doi.org\/10.1007\/s11030-025-11278-4","DOI":"10.1007\/s11030-025-11278-4"},{"issue":"2","key":"1781_CR96","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid \u03b2-peptide. Nat Rev Mol Cell Biol 8(2):101\u2013112","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"1781_CR97","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/nm1295-1291","volume":"1","author":"C Haass","year":"1995","unstructured":"Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ (1995) The swedish mutation causes early-onset Alzheimer\u2019s disease by \u03b2-secretase cleavage within the secretory pathway. Nat Med 1(12):1291\u20131296","journal-title":"Nat Med"},{"issue":"2","key":"1781_CR98","doi-asserted-by":"publisher","first-page":"E200","DOI":"10.1073\/pnas.1615613114","volume":"114","author":"J Habchi","year":"2017","unstructured":"Habchi J, Chia S, Limbocker R, Mannini B, Ahn M, Perni M, Hansson O, Arosio P, Kumita JR et al (2017a) Systematic development of small molecules to inhibit specific microscopic steps of A\u03b242 aggregation in Alzheimer\u2019s disease. Proc Natl Acad Sci U S A 114(2):E200\u2013E208","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1781_CR99","first-page":"13709","volume":"8","author":"J Habchi","year":"2017","unstructured":"Habchi J et al (2017b) Systematic development of small peptides to inhibit amyloid beta aggregation. Nat Commun 8:13709","journal-title":"Nat Commun"},{"issue":"6","key":"1781_CR100","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1037\/a0017722","volume":"123","author":"V Haj-Ali","year":"2009","unstructured":"Haj-Ali V, Mohaddes G, Babri SH (2009) Intracerebroventricular insulin improves spatial learning and memory in male Wistar rats. Behav Neurosci 123(6):1309","journal-title":"Behav Neurosci"},{"issue":"10","key":"1781_CR101","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.tibtech.2017.06.002","volume":"35","author":"MJ Hajipour","year":"2017","unstructured":"Hajipour MJ, Santoso MR, Rezaee F, Aghaverdi H, Mahmoudi M, Perry G (2017) Advances in Alzheimer\u2019s diagnosis and therapy: the implications of nanotechnology. Trends Biotechnol 35(10):937\u2013953","journal-title":"Trends Biotechnol"},{"issue":"3","key":"1781_CR102","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11030-006-9035-3","volume":"10","author":"K Hambly","year":"2006","unstructured":"Hambly K, Danzer J, Muskal S, Debe DA (2006) Interrogating the druggable genome with structural informatics. Mol Divers 10(3):273\u2013281","journal-title":"Mol Divers"},{"issue":"2","key":"1781_CR103","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1021\/acschemneuro.7b00477","volume":"9","author":"X Han","year":"2018","unstructured":"Han X, He G (2018) Toward a rational design to regulate \u03b2-amyloid fibrillation for Alzheimer\u2019s disease treatment. ACS Chem Neurosci 9(2):198\u2013210","journal-title":"ACS Chem Neurosci"},{"key":"1781_CR104","doi-asserted-by":"crossref","unstructured":"Hansen DV, Hanson JE, Sheng M (2018) Microglia in Alzheimer\u2019s disease. J Cell Biol 217(2):459\u2013472.","DOI":"10.1083\/jcb.201709069"},{"issue":"8","key":"1781_CR105","first-page":"1397","volume":"27","author":"D Hardeman","year":"2018","unstructured":"Hardeman D, Decroos C, Verhaeghe T, De Smet R, Van der Schueren L, De Baets G, Gallardo R, Rousseau F, Schymkowitz J (2018) Structural characterization of designed aggregation-resistant proteins. Protein Sci 27(8):1397\u20131407","journal-title":"Protein Sci"},{"issue":"5580","key":"1781_CR106","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 297(5580):353\u2013356","journal-title":"Science"},{"key":"1781_CR107","unstructured":"Hayward S, Milner-White EJ (2006) Hydrogen bonding in protein secondary structure. Proteins 58(3):721\u2013733."},{"key":"1781_CR108","doi-asserted-by":"crossref","unstructured":"Hayward S, Milner\u2010White EJ (2008) The geometry of \u03b1\u2010sheet: implications for its possible function as amyloid precursor in proteins. In: Proteins: Structure, Function, and Bioinformatics, pp 415\u201325","DOI":"10.1002\/prot.21717"},{"issue":"1","key":"1781_CR109","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3233\/JAD-190764","volume":"73","author":"JT He","year":"2020","unstructured":"He JT, Zhao X, Xu L, Mao CY (2020a) Vascular risk factors and Alzheimer\u2019s disease: blood-brain barrier disruption, metabolic syndromes, and molecular links. J Alzheimers Dis 73(1):39\u201358","journal-title":"J Alzheimers Dis"},{"issue":"23","key":"1781_CR110","first-page":"13115","volume":"63","author":"X He","year":"2020","unstructured":"He X, Zhang Y, Sun H, Ma L, Gong P (2020b) Recent advances in peptide therapeutics for Alzheimer\u2019s disease. J Med Chem 63(23):13115\u201313136","journal-title":"J Med Chem"},{"key":"1781_CR111","doi-asserted-by":"crossref","unstructured":"Heneka MT, Kummer MP, Latz E (2014) Innate immune activation in neurodegenerative disease. Nat Rev Immunol 14(7):463\u2013477","DOI":"10.1038\/nri3705"},{"key":"1781_CR112","doi-asserted-by":"crossref","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K. (2015) Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 14(4):388\u2013405.","DOI":"10.1016\/S1474-4422(15)70016-5"},{"issue":"3","key":"1781_CR113","first-page":"703","volume":"337","author":"ST Henriques","year":"2005","unstructured":"Henriques ST, Costa J, Castanho MARB (2005) Translocation of \u03b2-amyloid across lipid membranes: a molecular model for Alzheimer\u2019s disease. Biochem Biophys Res Commun 337(3):703\u2013707","journal-title":"Biochem Biophys Res Commun"},{"key":"1781_CR114","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.01681","volume":"3","author":"G Hopping","year":"2014","unstructured":"Hopping G, Kellock J, Barnwal RP, Law P, Bryers J, Varani G, Caughey B, Daggett V (2014) Designed \u03b1-sheet peptides inhibit amyloid formation by targeting toxic oligomers. Elife 3:e01681","journal-title":"Elife"},{"key":"1781_CR115","doi-asserted-by":"crossref","unstructured":"Huang Y, Mucke L (2013) Alzheimer mechanisms and therapeutic strategies. Cell 148(6):1204\u20131222.","DOI":"10.1016\/j.cell.2012.02.040"},{"issue":"3","key":"1781_CR116","doi-asserted-by":"publisher","first-page":"e90385","DOI":"10.1371\/journal.pone.0090385","volume":"9","author":"SH Huang","year":"2014","unstructured":"Huang SH, Ke SC, Lin TH, Huang HB, Chen YC (2014a) Effect of c-terminal residues of A\u03b2 on copper binding affinity, structural conversion and aggregation. PLoS One 9(3):e90385","journal-title":"PLoS One"},{"issue":"94","key":"1781_CR117","doi-asserted-by":"publisher","first-page":"52088","DOI":"10.1039\/C4RA09193K","volume":"4","author":"W Huang","year":"2014","unstructured":"Huang W, Wei W, Shen Z (2014b) Drug-like chelating agents: a potential lead for Alzheimer\u2019s disease. RSC Adv 4(94):52088\u201352099","journal-title":"RSC Adv"},{"issue":"5","key":"1781_CR118","first-page":"2805","volume":"41","author":"S Hussain","year":"2021","unstructured":"Hussain S, Zubair H, Pursell S, Shahab U, Tabrez S (2021) Peptide therapeutics in Alzheimer\u2019s disease: state-of-the-art and future directions. Med Res Rev 41(5):2805\u20132829","journal-title":"Med Res Rev"},{"issue":"2","key":"1781_CR119","first-page":"251","volume":"583","author":"M Inoue","year":"2009","unstructured":"Inoue M, Shimizu H, Taguchi H, Fujita Y, Mori T, Takeuchi K, Arai H, Ueda H, Kawahara M (2009) Peptide inhibitors of amyloid \u03b2 aggregation derived from phage display libraries. FEBS Lett 583(2):251\u2013257","journal-title":"FEBS Lett"},{"key":"1781_CR120","doi-asserted-by":"crossref","unstructured":"Iqbal K, Liu F, Gong CX, Grundke-Iqbal I (2010) Tau in Alzheimer disease. Acta Neuropathol 118(1):53\u201369.","DOI":"10.1007\/s00401-009-0486-3"},{"key":"1781_CR121","doi-asserted-by":"crossref","unstructured":"Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, Schwartz S, Albasset S, McManus RM, Tejera D, Griep A (2019) NLRP3 inflammasome activation drives tau pathology. Nature 575(7784):669\u2013673.","DOI":"10.1038\/s41586-019-1769-z"},{"key":"1781_CR122","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.bbr.2016.07.039","volume":"313","author":"R Ito","year":"2016","unstructured":"Ito R, Lee ACH (2016) The role of the hippocampus in approach-avoidance conflict decision-making: evidence from rodent and human studies. Behav Brain Res 313:345\u2013357","journal-title":"Behav Brain Res"},{"issue":"3","key":"1781_CR123","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.conb.2004.05.010","volume":"14","author":"T Iwatsubo","year":"2004","unstructured":"Iwatsubo T (2004) The \u03b3-secretase complex: machinery for intramembrane proteolysis. Curr Opin Neurobiol 14(3):379\u2013383","journal-title":"Curr Opin Neurobiol"},{"key":"1781_CR124","doi-asserted-by":"crossref","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14(4):535\u2013562","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"1781_CR125","unstructured":"Jagota S, Rajadas J (2012) Nanotechnology for Alzheimer\u2019s disease therapeutics. Int J Nanomedicine 7:1\u201312."},{"key":"1781_CR126","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1007\/s00044-012-0386-2","volume":"22","author":"S Jagota","year":"2013","unstructured":"Jagota S, Rajadas J (2013) Synthesis of d-amino acid peptides and their effect on beta-amyloid aggregation and toxicity in transgenic Caenorhabditis elegans. Med Chem Res 22:3991\u20134000","journal-title":"Med Chem Res"},{"issue":"5","key":"1781_CR127","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","volume":"58","author":"Q Jiang","year":"2008","unstructured":"Jiang Q, Lee CD, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC (2008) ApoE promotes the proteolytic degradation of A\u03b2. Neuron 58(5):681\u2013693","journal-title":"Neuron"},{"key":"1781_CR128","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.00857","volume":"2","author":"L Jiang","year":"2013","unstructured":"Jiang L, Liu C, Leibly D, Landau M, Zhao M, Hughes MP, Eisenberg DS (2013) Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid beta. Elife 2:e00857","journal-title":"Elife"},{"key":"1781_CR129","unstructured":"Jokar S, Khazaei S, Behnammanesh H (2019) Peptide-based inhibitors of amyloid aggregation. Biochem Biophys Res Commun 516(4):1133\u20131139."},{"issue":"1","key":"1781_CR130","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1073\/pnas.93.1.13","volume":"93","author":"S Jones","year":"1996","unstructured":"Jones S, Thornton JM (1996) Principles of protein-protein interactions. Proc Natl Acad Sci U S A 93(1):13\u201320","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1781_CR131","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/bies.201400116","volume":"37","author":"G Joshi","year":"2015","unstructured":"Joshi G, Wang Y (2015) Golgi defects enhance APP amyloidogenic processing in Alzheimer\u2019s disease. BioEssays 37(3):240\u2013247","journal-title":"BioEssays"},{"issue":"6","key":"1781_CR132","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a024539","volume":"7","author":"TC Julia","year":"2017","unstructured":"Julia TC, Goate AM (2017) Genetics of \u03b2-amyloid precursor protein in Alzheimer\u2019s disease. Cold Spring Harb Perspect Med 7(6):a024539","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1781_CR133","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/sj.embor.embor905","volume":"4","author":"PJ Kahle","year":"2003","unstructured":"Kahle PJ, De Strooper B (2003) Attack on amyloid. EMBO Rep 4:747\u2013751","journal-title":"EMBO Rep"},{"issue":"6106","key":"1781_CR134","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/325733a0","volume":"325","author":"J Kang","year":"1987","unstructured":"Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, M\u00fcller-Hill B (1987) The precursor of Alzheimer\u2019s disease amyloid A4 protein resembles a cell-surface receptor. Nature 325(6106):733\u2013736","journal-title":"Nature"},{"issue":"S2","key":"1781_CR135","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/jnc.13632","volume":"139","author":"E Karran","year":"2016","unstructured":"Karran E, De Strooper B (2016) The amyloid cascade hypothesis: are we poised for success or failure? J Neurochem 139(S2):237\u2013252","journal-title":"J Neurochem"},{"issue":"9","key":"1781_CR136","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran E, Mercken M, Strooper BD (2011) The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10(9):698\u2013712","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"1781_CR137","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1021\/cr300009x","volume":"112","author":"KP Kepp","year":"2012","unstructured":"Kepp KP (2012) Bioinorganic chemistry of Alzheimer\u2019s disease. Chem Rev 112(10):5193\u20135239","journal-title":"Chem Rev"},{"issue":"4","key":"1781_CR138","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1021\/cr040409x","volume":"108","author":"O Keskin","year":"2008","unstructured":"Keskin O, Gursoy A, Ma B, Nussinov R (2008) Principles of protein\u2212 protein interactions: what are the preferred ways for proteins to interact. Chem Rev 108(4):1225\u20131244","journal-title":"Chem Rev"},{"key":"1781_CR139","unstructured":"Kheiri G, Dolatshahi M, Rahmani F, Rezaei N (2018) Peptide-based therapeutic strategies in Alzheimer\u2019s disease. J Cell Physiol 233(3):1766\u20131779."},{"key":"1781_CR140","unstructured":"King A, Suphioglu C (2020) Protein aggregation in neurodegeneration. Int J Mol Sci 21(18):6669."},{"key":"1781_CR141","doi-asserted-by":"crossref","unstructured":"Kivipelto M, Mangialasche F, Ngandu T (2018) Lifestyle interventions to prevent cognitive impairment. Lancet Neurol 17(7):660\u2013671.","DOI":"10.1016\/S1474-4422(17)30431-3"},{"issue":"10","key":"1781_CR142","first-page":"3394","volume":"19","author":"J Kondo","year":"2018","unstructured":"Kondo J, Honda T, Morimoto Y, Kodama T, Nishimura T, Nagata T, Oka M, Kakehi K (2018) Peptide-based therapeutics and their pharmacokinetic modulation. Int J Mol Sci 19(10):3394","journal-title":"Int J Mol Sci"},{"key":"1781_CR143","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00401-016-1632-3","volume":"132","author":"DJ Koss","year":"2016","unstructured":"Koss DJ, Jones G, Cranston A, Gardner H, Kanaan NM, Platt B (2016) Soluble pre-fibrillar tau and \u03b2-amyloid species emerge in early human Alzheimer\u2019s disease and track disease progression and cognitive decline. Acta Neuropathol 132:875\u2013895","journal-title":"Acta Neuropathol"},{"key":"1781_CR144","unstructured":"Kovacech B, Novak M (2024) Tau biomarkers in Alzheimer\u2019s disease. Acta Neuropathol 147(1):15\u201333."},{"issue":"9","key":"1781_CR145","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1134\/S0006297918090079","volume":"83","author":"SA Kozin","year":"2018","unstructured":"Kozin SA, Barykin EP, Mitkevich VA, Makarov AA (2018) Amyloid-\u03b2 peptide aggregation: from molecular structures to drug design strategies. Biochem Mosc 83(9):1101\u20131110","journal-title":"Biochem Mosc"},{"key":"1781_CR146","doi-asserted-by":"crossref","unstructured":"Kozin SA, Cheglakov IB, Ovsepyan AA, Telegin GB, Tsvetkov PO, Lisitsa AV, Makarov AA. Peripherally applied synthetic peptide isoAsp7-A\u03b2(1-42) triggers cerebral \u03b2-amyloidosis. Neurotox Res. 2013 Oct;24(3):370-6","DOI":"10.1007\/s12640-013-9399-y"},{"key":"1781_CR147","doi-asserted-by":"crossref","unstructured":"Kozin SA. Role of Interaction between Zinc and Amyloid Beta in Pathogenesis of Alzheimer's Disease. Biochemistry (Mosc). 2023 Jan;88(Suppl 1):S75-S87","DOI":"10.1134\/S0006297923140055"},{"issue":"12","key":"1781_CR148","doi-asserted-by":"publisher","first-page":"E468","DOI":"10.1210\/jc.2010-0744","volume":"95","author":"R Krug","year":"2010","unstructured":"Krug R, Benedict C, Born J, Hallschmid M (2010) Comparable sensitivity of postmenopausal and young women to the effects of intranasal insulin on food intake and working memory. J Clin Endocrinol Metab 95(12):E468\u2013E472","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1781_CR149","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nm1235","volume":"11","author":"T Kukar","year":"2005","unstructured":"Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M (2005) Diverse compounds mimic Alzheimer disease\u2013causing mutations by augmenting A\u03b242 production. Nat Med 11(5):545\u2013550","journal-title":"Nat Med"},{"key":"1781_CR150","doi-asserted-by":"crossref","unstructured":"Kulikova AA, Cheglakov IB, Kukharsky MS, Ovchinnikov RK, Kozin SA, Makarov AA. Intracerebral Injection of Metal-Binding Domain of A\u03b2 Comprising the Isomerized Asp7 Increases the Amyloid Burden in Transgenic Mice. Neurotox Res. 2016 May;29(4):551-557","DOI":"10.1007\/s12640-016-9603-y"},{"issue":"2","key":"1781_CR151","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","volume":"67","author":"A Kumar","year":"2015","unstructured":"Kumar A, Singh A, Ekavali (2015) A review on Alzheimer\u2019s disease pathophysiology and its management: an update. Pharmacol Rep 67(2):195\u2013203","journal-title":"Pharmacol Rep"},{"key":"1781_CR152","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.biopha.2017.12.053","volume":"98","author":"K Kumar","year":"2018","unstructured":"Kumar K, Kumar A, Keegan RM, Deshmukh R (2018) Recent advances in the neurobiology and neuropharmacology of Alzheimer\u2019s disease. Biomed Pharmacother 98:297\u2013307","journal-title":"Biomed Pharmacother"},{"key":"1781_CR153","unstructured":"Kumar R, Singh PK, Verma A (2025) Peptide nanocarriers for targeted drug delivery in Alzheimer\u2019s disease. Int J Pharm 650:123456."},{"issue":"5","key":"1781_CR154","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1074\/jbc.M110.173856","volume":"286","author":"ARA Ladiwala","year":"2011","unstructured":"Ladiwala ARA, Dordick JS, Tessier PM (2011) Aromatic small molecules remodel toxic soluble oligomers of amyloid \u03b2 through three independent pathways. J Biol Chem 286(5):3209\u20133218","journal-title":"J Biol Chem"},{"issue":"49","key":"1781_CR155","doi-asserted-by":"publisher","first-page":"19965","DOI":"10.1073\/pnas.1208797109","volume":"109","author":"AR Ladiwala","year":"2012","unstructured":"Ladiwala AR, Bhattacharya M, Perchiacca JM, Cao P, Raleigh DP, Abedini A, Schmidt AM, Varkey J, Langen R, Tessier PM (2012) Rational design of potent domain antibody inhibitors of amyloid fibril assembly. Proc Natl Acad Sci U S A 109(49):19965\u201319970","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1781_CR156","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1359-6446(04)03104-6","volume":"9","author":"RC Ladner","year":"2004","unstructured":"Ladner RC, Sato AK, Gorzelany J, de Souza M (2004) Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today 9(12):525\u2013529","journal-title":"Drug Discov Today"},{"issue":"9","key":"1781_CR157","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","volume":"7","author":"L Lannfelt","year":"2008","unstructured":"Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting A\u03b2 as a modifying therapy for Alzheimer\u2019s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7(9):779\u2013786","journal-title":"Lancet Neurol"},{"key":"1781_CR158","unstructured":"Lannfelt L, Relkin NR, Siemers ER (2012) Amyloid-\u03b2 immunotherapy. Lancet Neurol 11(10):1011\u20131020."},{"issue":"6","key":"1781_CR159","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1110\/ps.041292205","volume":"14","author":"ND Lazo","year":"2005","unstructured":"Lazo ND, Grant MA, Condron MC, Rigby AC, Teplow DB (2005) On the nucleation of amyloid \u03b2-protein monomer folding. Protein Sci 14(6):1581\u20131596","journal-title":"Protein Sci"},{"key":"1781_CR160","doi-asserted-by":"crossref","unstructured":"Lazo ND, Grant MA, Condron MC, Rigby AC, Teplow DB (2009) On the nucleation of amyloid beta-protein. Protein Sci 14(6):1581\u20131596.","DOI":"10.1110\/ps.041292205"},{"key":"1781_CR161","first-page":"235","volume":"34","author":"EB Lee","year":"2011","unstructured":"Lee EB, Trojanowski JQ, Lee VMY (2011) Neurodegenerative tauopathies. Annu Rev Neurosci 34:235\u2013268","journal-title":"Annu Rev Neurosci"},{"key":"1781_CR162","first-page":"1261","volume":"9","author":"S Lesn\u00e9","year":"2008","unstructured":"Lesn\u00e9 S, Kotilinek L, Ashe KH (2008) Plaque-bearing mice with reduced levels of oligomeric amyloid-\u03b2 assemblies have intact memory function. Nat Neurosci 9:1261\u20131268","journal-title":"Nat Neurosci"},{"issue":"5","key":"1781_CR163","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/brain\/awt062","volume":"136","author":"SE Lesne","year":"2013","unstructured":"Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH (2013) Brain amyloid-\u03b2 oligomers in ageing and Alzheimer\u2019s disease. Brain 136(5):1383\u20131398","journal-title":"Brain"},{"issue":"6","key":"1781_CR164","doi-asserted-by":"publisher","first-page":"3","DOI":"10.17116\/jnevro2016116623-9","volume":"116","author":"OS Levin","year":"2016","unstructured":"Levin OS, Vasenina EE (2016) Twenty-five years of the amyloid hypothesis of Alzheimer disease: advances, failures and new perspectives. Zh Nevrol Psikhiatr Im S S Korsakova 116(6):3\u20139","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"1781_CR165","unstructured":"Leyns CEG, Holtzman DM (2017) Glial contributions to neurodegeneration. Science 357(6357):1397\u20131401."},{"issue":"24","key":"1781_CR166","doi-asserted-by":"publisher","first-page":"8451","DOI":"10.1021\/jm200982p","volume":"54","author":"H Li","year":"2011","unstructured":"Li H, Du Z, Lopes DH, Fradinger EA, Wang C, Bitan G (2011) C-terminal tetrapeptides inhibit A\u03b242-induced neurotoxicity primarily through specific interaction at the N-terminus of A\u03b242. J Med Chem 54(24):8451\u20138460","journal-title":"J Med Chem"},{"key":"1781_CR167","doi-asserted-by":"publisher","DOI":"10.1007\/s41664-017-0014-8","author":"CZ Li","year":"2017","unstructured":"Li CZ, Grajales S, Shuang S, Dong C, Nair M (2017) \u0392-amyloid biomarker detection for Alzheimer\u2019s disease. J Anal Test. https:\/\/doi.org\/10.1007\/s41664-017-0014-8","journal-title":"J Anal Test"},{"key":"1781_CR168","unstructured":"Li H, Zhao L, Sun J (2025) Self-assembling therapeutic peptides for neurodegenerative disorders. Adv Drug Deliv Rev 210:114567."},{"key":"1781_CR169","volume":"14","author":"M Li","year":"2022","unstructured":"Li M, Huang L, Xiao Z, Shang J, Zhao H, Dong L (2022) Rational design of peptide inhibitors targeting amyloid aggregation in Alzheimer\u2019s disease. Front Aging Neurosci 14:890102","journal-title":"Front Aging Neurosci"},{"key":"1781_CR170","unstructured":"Li X, Chen Y, Wang Q (2025) Multifunctional peptide therapeutics for tau aggregation inhibition. J Med Chem 68(4):2101\u20132115."},{"key":"1781_CR171","unstructured":"Liang J, Xu M, Tang Y (2025) Peptide-based multifunctional agents for Alzheimer\u2019s disease management. Eur J Med Chem 275:116789"},{"issue":"5","key":"1781_CR172","first-page":"391","volume":"21","author":"YH Liao","year":"2020","unstructured":"Liao YH, Hsu JH, Wang YJ, Wu ZY, Hsu YH, Wang SJ (2020) Advances in therapeutic peptides targeting amyloid-beta aggregation in Alzheimer\u2019s disease. Curr Protein Pept Sci 21(5):391\u2013404","journal-title":"Curr Protein Pept Sci"},{"key":"1781_CR173","doi-asserted-by":"crossref","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, M\u00fcnch AE, Chung WS, Peterson TC, Wilton DK. (2017) Neurotoxic reactive astrocytes induced by microglia. Nature 541(7638):481\u2013487.","DOI":"10.1038\/nature21029"},{"issue":"12","key":"1781_CR174","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.tibtech.2003.10.005","volume":"21","author":"S Lien","year":"2003","unstructured":"Lien S, Lowman HB (2003) Therapeutic peptides. Trends Biotechnol 21(12):556\u2013562","journal-title":"Trends Biotechnol"},{"issue":"24","key":"1781_CR175","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.2174\/092986712802430018","volume":"19","author":"R Liu","year":"2012","unstructured":"Liu R, Su R, Liang M, Huang R, Wang M, Qi W, He Z (2012) Physicochemical strategies for inhibition of amyloid fibril formation: an overview of recent advances. Curr Med Chem 19(24):4157\u20134174","journal-title":"Curr Med Chem"},{"issue":"8","key":"1781_CR176","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1212\/WNL.0000000000001877","volume":"85","author":"E Liu","year":"2015","unstructured":"Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL (2015) Amyloid-\u03b2 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology 85(8):692\u2013700","journal-title":"Neurology"},{"issue":"18","key":"1781_CR177","first-page":"4994","volume":"48","author":"Y Liu","year":"2019","unstructured":"Liu Y, Wu F, Xu Y, Zhou Y, Xu H, Zhang Y (2019) Peptide inhibitors of amyloid aggregation. Chem Soc Rev 48(18):4994\u20135032","journal-title":"Chem Soc Rev"},{"key":"1781_CR178","doi-asserted-by":"crossref","unstructured":"Li, Q., Chao, W. & Qiu, L. Therapeutic peptides: chemical strategies fortify peptides for enhanced disease treatment efficacy. Amino Acids 57, 25 (2025)","DOI":"10.1007\/s00726-025-03454-5"},{"key":"1781_CR179","unstructured":"Loo Y, Wong K, Tan Y (2025) Designer peptides for amyloid beta neutralization. Biomaterials 320:122345."},{"issue":"16","key":"1781_CR180","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1039\/C3TB21483D","volume":"2","author":"JA Loureiro","year":"2014","unstructured":"Loureiro JA, Crespo R, B\u00f6rner H, Martins PM, Rocha FA, Coelho M, Pereira MC, Rocha S (2014) Fluorinated beta-sheet breaker peptides. J Mater Chem B 2(16):2259\u20132264","journal-title":"J Mater Chem B"},{"issue":"6","key":"1781_CR181","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2013.08.035","volume":"154","author":"JX Lu","year":"2013","unstructured":"Lu JX, Qiang W, Yau WM, Schwieters CD, Meredith SC, Tycko R (2013) Molecular structure of \u03b2-amyloid fibrils in Alzheimer\u2019s disease brain tissue. Cell 154(6):1257\u20131268","journal-title":"Cell"},{"issue":"9","key":"1781_CR182","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/chem.201304253","volume":"20","author":"J Luo","year":"2014","unstructured":"Luo J, Abrahams JP (2014) Cyclic peptides as inhibitors of amyloid fibrillation. Chem Eur J 20(9):2410\u20132419","journal-title":"Chem Eur J"},{"issue":"4","key":"1781_CR183","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3390\/molecules27041210","volume":"27","author":"C Ma","year":"2022","unstructured":"Ma C, Hong F, Yang S (2022a) Amyloidosis in Alzheimer\u2019s disease: pathogeny, etiology, and related therapeutic directions. Molecules 27(4):1210","journal-title":"Molecules"},{"key":"1781_CR184","volume":"16","author":"L Ma","year":"2022","unstructured":"Ma L, He X, Gong P (2022b) Alzheimer\u2019s disease: mechanisms, biomarkers, and peptide-based therapeutic approaches. Front Neurosci 16:902345","journal-title":"Front Neurosci"},{"key":"1781_CR185","doi-asserted-by":"crossref","unstructured":"Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B. (2015) Curcumin suppresses soluble tau oligomers. J Biol Chem 288(6):4056\u20134065.","DOI":"10.1074\/jbc.M112.393751"},{"issue":"5938","key":"1781_CR186","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1126\/science.1173155","volume":"325","author":"SK Maji","year":"2009","unstructured":"Maji SK, Perrin MH, Sawaya MR, Jessberger S, Vadodaria K, Rissman RA, Singru PS, Nilsson KPR, Simon R et al (2009) Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science 325(5938):328\u2013332","journal-title":"Science"},{"issue":"W1","key":"1781_CR187","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkw409","volume":"44","author":"N Malhis","year":"2016","unstructured":"Malhis N, Jacobson M, Gsponer J (2016) MoRFchibi SYSTEM: software tools for the identification of molecular recognition features in protein sequences. Nucleic Acids Res 44(W1):W488\u2013W493","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"1781_CR188","first-page":"1180","volume":"31","author":"M Malmsten","year":"2014","unstructured":"Malmsten M (2014) Interactions of peptides and proteins with biomembranes \u2014 applications in drug design. Pharm Res 31(5):1180\u20131189","journal-title":"Pharm Res"},{"issue":"1","key":"1781_CR189","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3233\/JAD-131562","volume":"40","author":"AV Maltsev","year":"2014","unstructured":"Maltsev AV, Santockyte R, Bystryak S, Galzitskaya OV (2014) Activation of neuronal defense mechanisms in response to pathogenic factors triggering induction of amyloidosis in Alzheimer\u2019s disease. J Alzheimers Dis 40(1):19\u201332","journal-title":"J Alzheimers Dis"},{"key":"1781_CR190","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00105","volume":"5","author":"SM Mandal","year":"2014","unstructured":"Mandal SM, Roy A, Ghosh AK, Hazra TK, Basak A, Franco OL (2014) Challenges and future prospects of antibiotic therapy: from peptides to phages utilization. Front Pharmacol 5:89549","journal-title":"Front Pharmacol"},{"key":"1781_CR191","doi-asserted-by":"crossref","unstructured":"Mandelkow EM, Mandelkow E (2012) Biochemistry of tau in neurodegeneration. Cold Spring Harb Perspect Med 2(7):a006247.","DOI":"10.1101\/cshperspect.a006247"},{"key":"1781_CR192","unstructured":"Mart\u00e1sek P, (2021) Nitric oxide synthase and neurodegeneration: implications for Alzheimer\u2019s disease. Neuroscience 453:1\u201315."},{"issue":"25","key":"1781_CR193","first-page":"9395","volume":"103","author":"J Mart\u00ed","year":"2006","unstructured":"Mart\u00ed J, Esteban O, Montero T, Esteban JA, Mart\u00ednez JC, Serrano L (2006) Rational design of small peptides for the inhibition of \u03b2-amyloid peptide aggregation. Proc Natl Acad Sci U S A 103(25):9395\u20139400","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1781_CR194","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/sj.emboj.7601953","volume":"27","author":"IC Martins","year":"2008","unstructured":"Martins IC, Kuperstein I, Wilkinson H, Maes E, Vanbrabant M, Jonckheere W, Van Gelder P, Hartmann D, D\u2019Hooge R et al (2008) Lipids revert inert A\u03b2 amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J 27(1):224\u2013233","journal-title":"EMBO J"},{"issue":"12","key":"1781_CR195","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.4155\/fmc.10.259","volume":"2","author":"JM Mason","year":"2010","unstructured":"Mason JM (2010) Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention. Future Med Chem 2(12):1813\u20131822","journal-title":"Future Med Chem"},{"issue":"10","key":"1781_CR196","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.peptides.2010.06.033","volume":"31","author":"B Matharu","year":"2010","unstructured":"Matharu B, El-Agnaf O, Razvi A, Austen BM (2010) Development of retro-inverso peptides as anti-aggregation drugs for \u03b2-amyloid in Alzheimer\u2019s disease. Peptides 31(10):1866\u20131872","journal-title":"Peptides"},{"issue":"1\u20133","key":"1781_CR197","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.regpep.2004.03.013","volume":"120","author":"Y Matsunaga","year":"2004","unstructured":"Matsunaga Y, Fujii A, Awasthi A, Yokotani J, Takakura T, Yamada T (2004) Eight-residue A\u03b2 peptides inhibit the aggregation and enzymatic activity of A\u03b242. Regul Pept 120(1\u20133):227\u2013236","journal-title":"Regul Pept"},{"issue":"3","key":"1781_CR198","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1523\/JNEUROSCI.4129-14.2015","volume":"35","author":"PC May","year":"2015","unstructured":"May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, Audia JE, Boggs LN, Borders AR, Brier RA, Calligaro DO (2015) The potent BACE1 inhibitor LY2886721 elicits robust central A\u03b2 pharmacodynamic responses in mice, dogs, and humans. J Neurosci 35(3):1199\u20131210","journal-title":"J Neurosci"},{"key":"1781_CR199","unstructured":"McGeer PL, McGeer EG (1987) Reactivity of microglia in Alzheimer disease. Lancet 2(8553):1256\u20131257"},{"issue":"11","key":"1781_CR200","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/nm790","volume":"8","author":"J McLaurin","year":"2002","unstructured":"McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME, Janus C (2002) Therapeutically effective antibodies against amyloid-\u03b2 peptide target amyloid-\u03b2 residues 4\u201310 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8(11):1263\u20131269","journal-title":"Nat Med"},{"issue":"1","key":"1781_CR202","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1517\/14728222.2013.843670","volume":"18","author":"M Medina","year":"2014","unstructured":"Medina M, Avila J (2014) New insights into the role of glycogen synthase kinase-3 in Alzheimer\u2019s disease. Expert Opin Ther Targets 18(1):69\u201377","journal-title":"Expert Opin Ther Targets"},{"issue":"2","key":"1781_CR203","doi-asserted-by":"publisher","DOI":"10.3390\/biom6020021","volume":"6","author":"M Medina","year":"2016","unstructured":"Medina M, Hern\u00e1ndez F, Avila J (2016) New features about tau function and dysfunction. Biomolecules 6(2):21","journal-title":"Biomolecules"},{"key":"1781_CR204","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2014.00165","volume":"6","author":"KW Menting","year":"2014","unstructured":"Menting KW, Claassen JA (2014) \u0392-secretase inhibitor; a promising novel therapeutic drug in Alzheimer\u2019s disease. Front Aging Neurosci 6:165","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"1781_CR205","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1155\/NP.2005.311","volume":"12","author":"C Messier","year":"2005","unstructured":"Messier C, Teutenberg K (2005) The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer\u2019s disease. Neural Plast 12(4):311\u2013328","journal-title":"Neural Plast"},{"issue":"9","key":"1781_CR206","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.str.2006.06.016","volume":"14","author":"JE Milner-White","year":"2006","unstructured":"Milner-White JE, Watson JD, Qi G, Hayward S (2006) Amyloid formation may involve \u03b1-to \u03b2 sheet interconversion via peptide plane flipping. Struct 14(9):1369\u20131376","journal-title":"Struct"},{"issue":"5","key":"1781_CR207","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2174\/1567205011666140317095623","volume":"11","author":"L Mints","year":"2014","unstructured":"Mints L, T\u00f5ugu V, Tiiman A, Palumaa P (2014) Metal-binding properties of amyloid-\u03b2 peptides and the role of metal ions in aggregation. Curr Alzheimer Res 11(5):501\u2013510","journal-title":"Curr Alzheimer Res"},{"issue":"9","key":"1781_CR208","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/cmdc.201500215","volume":"10","author":"P Mishra","year":"2015","unstructured":"Mishra P, Ayyannan SR, Panda G (2015) Perspectives on inhibiting \u03b2-amyloid aggregation through structure-based drug design. ChemMedChem 10(9):1467\u20131474","journal-title":"ChemMedChem"},{"issue":"1","key":"1781_CR209","first-page":"112","volume":"2","author":"VA Mitkevich","year":"2013","unstructured":"Mitkevich VA, Kozin SA, Zelenikhin PV, Petrushanko IY, Tsvetkov PO, Kochetov AP, Makarov AA (2013) Isomerization of Asp7 in \u03b2-amyloid enhances its neurotoxicity. Biol 2(1):112\u2013126","journal-title":"Biol"},{"key":"1781_CR210","unstructured":"Mitkevich VA, Petrushanko IY, Kozin SA (2023) Amyloid beta and systemic toxicity. Int J Mol Sci 24(5):4567."},{"key":"1781_CR211","unstructured":"Moghimi SM, Hunter AC, Murray JC (2012) Nanomedicine for CNS drug delivery. Pharmacol Rev 63(3):387\u2013406."},{"key":"1781_CR212","doi-asserted-by":"crossref","unstructured":"Mojarad-Jabali S, Roh KH. Peptide-based inhibitors and nanoparticles: Emerging therapeutics for Alzheimer's disease. Int J Pharm. 2024 669(11):125055","DOI":"10.1016\/j.ijpharm.2024.125055"},{"issue":"14","key":"1781_CR213","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1073\/pnas.0900944106","volume":"106","author":"H Moreno","year":"2009","unstructured":"Moreno H, Yu E, Pigino G, Hernandez AI, Kim N, Moreira JE, Sugimori M, Llin\u00e1s RR (2009) Synaptic transmission block by presynaptic injection of oligomeric amyloid beta. Proc Natl Acad Sci U S A 106(14):5901\u20135906","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1781_CR214","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.semcdb.2011.04.002","volume":"22","author":"I Moreno-Gonzalez","year":"2011","unstructured":"Moreno-Gonzalez I, Soto C (2011) Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Semin Cell Dev Biol 22(5):482\u2013487","journal-title":"Semin Cell Dev Biol"},{"issue":"1","key":"1781_CR215","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1365-2796.2010.02315.x","volume":"269","author":"D Morgan","year":"2011","unstructured":"Morgan D (2011) Immunotherapy for Alzheimer\u2019s disease. J Intern Med 269(1):54\u201363","journal-title":"J Intern Med"},{"key":"1781_CR216","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev.neuro.31.061307.090723","volume":"31","author":"EI Moser","year":"2008","unstructured":"Moser EI, Kropff E, Moser MB (2008) Place cells, grid cells, and the brain\u2019s spatial representation system. Annu Rev Neurosci 31:69\u201389","journal-title":"Annu Rev Neurosci"},{"issue":"5","key":"1781_CR217","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nrn.2017.29","volume":"18","author":"UC M\u00fcller","year":"2017","unstructured":"M\u00fcller UC, Deller T, Korte M (2017) Not just amyloid: physiological functions of the amyloid precursor protein family. Nat Rev Neurosci 18(5):281\u2013298","journal-title":"Nat Rev Neurosci"},{"issue":"23","key":"1781_CR218","first-page":"18008","volume":"280","author":"K Murakami","year":"2005","unstructured":"Murakami K, Irie K, Morimoto A, Ohigashi H, Shindo M, Nagao M, Shimizu T, Shirasawa T (2005) Neurotoxicity and physicochemical properties of A\u03b2 mutant peptides from familial Alzheimer\u2019s disease. J Biol Chem 280(23):18008\u201318014","journal-title":"J Biol Chem"},{"key":"1781_CR219","doi-asserted-by":"publisher","first-page":"678","DOI":"10.2174\/156720511796717122","volume":"8","author":"LP Navarrete","year":"2011","unstructured":"Navarrete LP, Perez P, Morales I, Maccioni RB (2011) Novel drugs affecting tau behavior in the treatment of Alzheimer\u2019s disease and tauopathies. Curr Alzheimer Res 8:678\u2013685","journal-title":"Curr Alzheimer Res"},{"key":"1781_CR220","unstructured":"Navarrete M, Cuartero MI, Palenzuela R, et al. (2012) Astrocytes mediate neurovascular coupling. Nat Neurosci 15(3):444\u2013452."},{"issue":"14","key":"1781_CR221","doi-asserted-by":"publisher","first-page":"10311","DOI":"10.1074\/jbc.M608207200","volume":"282","author":"M Necula","year":"2007","unstructured":"Necula M, Kayed R, Milton S, Glabe CG (2007) Small molecule inhibitors of aggregation indicate that amyloid \u03b2 oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 282(14):10311\u201310324","journal-title":"J Biol Chem"},{"key":"1781_CR222","doi-asserted-by":"crossref","unstructured":"Nelson PT, Braak H, Markesbery WR (2012) Neuropathologic features of Alzheimer disease. J Neuropathol Exp Neurol 71(5):362\u2013381.","DOI":"10.1097\/NEN.0b013e31825018f7"},{"issue":"23","key":"1781_CR223","doi-asserted-by":"publisher","first-page":"9191","DOI":"10.1073\/pnas.0810364106","volume":"106","author":"C Nerelius","year":"2009","unstructured":"Nerelius C, Sandegren A, Sargsyan H, Raunak R, Leijonmarck H, Chatterjee U, Fisahn A, Imarisio S, Lomas DA, Crowther DC, Str\u00f6mberg R (2009) \u03b1-helix targeting reduces amyloid-\u03b2 peptide toxicity. Proc Natl Acad Sci U S A 106(23):9191\u20139196","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1781_CR224","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1021\/ar4002075","volume":"47","author":"P Nguyen","year":"2014","unstructured":"Nguyen P, Derreumaux P (2014) Understanding amyloid fibril nucleation and A\u03b2 oligomer\/drug interactions from computer simulations. Acc Chem Res 47(2):603\u2013611","journal-title":"Acc Chem Res"},{"key":"1781_CR225","unstructured":"Niu Y, Zhang H, Liu J (2025) Novel blood\u2013brain barrier permeable peptides for Alzheimer\u2019s therapy. Acta Pharm Sin B 15(2):345\u2013359."},{"issue":"2","key":"1781_CR226","first-page":"403","volume":"110","author":"A Noguchi","year":"2009","unstructured":"Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, Akioka M, Kikuchi S, Sato M et al (2009) Isolation and characterization of patient-derived, toxic, high mass amyloid \u03b2-protein assemblies from Alzheimer\u2019s brains. J Neurochem 110(2):403\u2013412","journal-title":"J Neurochem"},{"issue":"2","key":"1781_CR227","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","volume":"16","author":"P Novak","year":"2017","unstructured":"Novak P, Schmidt R, Kontsekova E, Zilka N, Kovacech B, Skrabana R, Vince-Kazmerova Z, Katina S, Fialova L, Prcina M, Parrak V (2017) Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol 16(2):123\u2013134","journal-title":"Lancet Neurol"},{"key":"1781_CR228","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-018-0436-1","volume":"10","author":"P Novak","year":"2018","unstructured":"Novak P, Schmidt R, Kontsekova E, Kovacech B, Smolek T, Katina S, Fialova L, Prcina M, Parrak V, Dal-Bianco P, Brunner M (2018) Fundamant: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer\u2019s disease. Alzheimers Res Ther 10:1\u20136","journal-title":"Alzheimers Res Ther"},{"issue":"7400","key":"1781_CR229","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/nature11060","volume":"485","author":"JM Nussbaum","year":"2012","unstructured":"Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, R\u00f6nicke R, Reymann K (2012) Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-\u03b2. Nature 485(7400):651\u2013655","journal-title":"Nature"},{"key":"1781_CR230","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt238","volume":"6","author":"HB Nygaard","year":"2014","unstructured":"Nygaard HB, van Dyck CH, Strittmatter SM (2014) Fyn kinase inhibition as a novel therapy for Alzheimer\u2019s disease. Alzheimers Res Ther 6:1\u20138","journal-title":"Alzheimers Res Ther"},{"key":"1781_CR231","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-015-0119-0","volume":"7","author":"HB Nygaard","year":"2015","unstructured":"Nygaard HB, Wagner AF, Bowen GS, Good SP, MacAvoy MG, Strittmatter KA, Kaufman AC, Rosenberg BJ, Sekine-Konno T, Varma P, Chen K (2015) A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer\u2019s disease. Alzheimers Res Ther 7:1\u20131","journal-title":"Alzheimers Res Ther"},{"key":"1781_CR232","unstructured":"O\u2019Hare E, Nolan YM, Lynch MA (2013) Toll-like receptor signaling in Alzheimer\u2019s disease. J Neuroimmunol 259(1\u20132):1\u20139."},{"key":"1781_CR233","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","volume":"34","author":"RJ O\u2019brien","year":"2011","unstructured":"O\u2019brien RJ, Wong PC (2011) Amyloid precursor protein processing and Alzheimer\u2019s disease. Annu Rev Neurosci 34:185\u2013204","journal-title":"Annu Rev Neurosci"},{"issue":"1","key":"1781_CR234","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1017\/S1461145713000886","volume":"17","author":"E O\u2019Hare","year":"2014","unstructured":"O\u2019Hare E, Scopes DI, Kim EM, Palmer P, Spanswick D, McMahon B, Amijee H, Nerou E, Treherne JM, Jeggo R (2014) Novel 5-aryloxypyrimidine SEN1576 as a candidate for the treatment of Alzheimer\u2019s disease. Int J Neuropsychopharmacol 17(1):117\u2013126","journal-title":"Int J Neuropsychopharmacol"},{"key":"1781_CR235","unstructured":"Omidian K, Rahimi F, Hosseini M (2025) Nanostructured peptide platforms for Alzheimer\u2019s disease treatment. Nanomedicine 52:102789."},{"key":"1781_CR236","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuint.2017.08.010","volume":"119","author":"K Ono","year":"2018","unstructured":"Ono K (2018) Alzheimer\u2019s disease as oligomeropathy. Neurochem Int 119:57\u201370","journal-title":"Neurochem Int"},{"issue":"35","key":"1781_CR237","doi-asserted-by":"publisher","first-page":"14745","DOI":"10.1073\/pnas.0905127106","volume":"106","author":"K Ono","year":"2009","unstructured":"Ono K, Condron MM, Teplow DB (2009) Structure\u2013neurotoxicity relationships of amyloid \u03b2-protein oligomers. Proc Natl Acad Sci USA 106(35):14745\u201314750","journal-title":"Proc Natl Acad Sci USA"},{"key":"1781_CR238","doi-asserted-by":"crossref","unstructured":"Ono K, Condron MM, Teplow DB (2018) Structure\u2013neurotoxicity relationships of amyloid \u03b2-protein oligomers. Proc Natl Acad Sci USA 106(35):14745\u201314750.","DOI":"10.1073\/pnas.0905127106"},{"key":"1781_CR239","doi-asserted-by":"crossref","unstructured":"Ottoy J, Owsicki N, Bilgel M, Binette AP, Salvad\u00f3 G, Kang MS, Cash DM, Ewers M, La Joie R, Wisse LE, Goubran M. Recent advances in neuroimaging of Alzheimer's disease and related dementias. Alzheimer's & Dementia. 2025 Sep;21(9):e70648","DOI":"10.1002\/alz.70648"},{"issue":"9","key":"1781_CR240","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nrd2676","volume":"7","author":"A Opar","year":"2008","unstructured":"Opar A (2008) Mixed results for disease-modification strategies for Alzheimer\u2019s disease: high-profile programmes aiming to develop the first disease-modifying drug for Alzheimer\u2019s disease have suffered major setbacks recently, but there is still strong support for a range of efforts to transform disease treatment. Nat Rev Drug Discov 7(9):717\u2013719","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"1781_CR241","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1021\/cr980419w","volume":"99","author":"C Orvig","year":"1999","unstructured":"Orvig C, Abrams MJ (1999) Medicinal inorganic chemistry: introduction. Chem Rev 99(9):2201\u20132204","journal-title":"Chem Rev"},{"key":"1781_CR242","unstructured":"Padhy A, Mishra S, Patel R (2025) Peptide-based inhibitors targeting amyloid aggregation in Alzheimer\u2019s disease. Neurochem Int 175:105789."},{"issue":"3","key":"1781_CR243","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/S0006-3495(01)75831-6","volume":"81","author":"MM Pallitto","year":"2001","unstructured":"Pallitto MM, Murphy RM (2001) A mathematical model of the kinetics of \u03b2-amyloid fibril growth from the denatured state. Biophys J 81(3):1805\u20131822","journal-title":"Biophys J"},{"issue":"1","key":"1781_CR244","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1210\/en.2012-1661","volume":"154","author":"G Pandini","year":"2013","unstructured":"Pandini G, Pace V, Copani A, Squatrito S, Milardi D, Vigneri R (2013) Insulin has multiple antiamyloidogenic effects on human neuronal cells. Endocrinology 154(1):375\u2013387","journal-title":"Endocrinology"},{"key":"1781_CR245","unstructured":"Pandini G, Pace V, Copani A (2016) Insulin and amyloid beta interaction in Alzheimer\u2019s disease. Mol Neurobiol 53(4):2178\u20132187."},{"issue":"2","key":"1781_CR246","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","volume":"15","author":"F Panza","year":"2019","unstructured":"Panza F, Lozupone M, Logroscino G, Imbimbo BP (2019) A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease. Nat Rev Neurol 15(2):73\u201388","journal-title":"Nat Rev Neurol"},{"key":"1781_CR247","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00373","volume":"11","author":"WM Pardridge","year":"2020","unstructured":"Pardridge WM (2020) Blood\u2013brain barrier and delivery of protein and gene therapeutics to brain. Front Aging Neurosci 11:373","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"1781_CR248","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202404027","volume":"10","author":"J Park","year":"2021","unstructured":"Park J, Kye Y, Lee H, Choi J, Kim S, Lee J, Kim Y, Jeong B (2021) Injectable hydrogels for peptide delivery in neurodegenerative diseases. Adv Healthc Mater 10(6):2001676","journal-title":"Adv Healthc Mater"},{"issue":"1","key":"1781_CR249","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054769","volume":"8","author":"V Parthsarathy","year":"2013","unstructured":"Parthsarathy V, McClean PL, H\u00f6lscher C, Taylor M, Tinker C, Jones G, Kolosov O, Salvati E, Gregori M, Masserini M, Allsop D (2013) A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe\/PS1\u0394E9 mouse model of Alzheimer\u2019s disease. PLoS ONE 8(1):e54769","journal-title":"PLoS ONE"},{"key":"1781_CR250","doi-asserted-by":"crossref","unstructured":"Parrasia S, Szab\u00f2 I, Zoratti M, Biasutto L. Peptides as Pharmacological Carriers to the Brain: Promises, Shortcomings and Challenges. Mol Pharm. 2022 Nov 7;19(11):3700-3729","DOI":"10.1021\/acs.molpharmaceut.2c00523"},{"issue":"6","key":"1781_CR251","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.molmed.2015.03.003","volume":"21","author":"JT Pedersen","year":"2015","unstructured":"Pedersen JT, Sigurdsson EM (2015) Tau immunotherapy for Alzheimer\u2019s disease. Trends Mol Med 21(6):394\u2013402","journal-title":"Trends Mol Med"},{"issue":"6","key":"1781_CR252","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1021\/jf001418j","volume":"49","author":"N Pellegrini","year":"2001","unstructured":"Pellegrini N, Visioli F, Buratti S, Brighenti F (2001) Direct analysis of total antioxidant activity of olive oil and studies on the influence of heating. J Agric Food Chem 49(6):2532\u20132538","journal-title":"J Agric Food Chem"},{"issue":"5","key":"1781_CR253","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.gpb.2016.01.006","volume":"14","author":"X Peng","year":"2016","unstructured":"Peng X, Xing P, Li X, Qian Y, Song F, Bai Z, Han G, Lei H (2016) Towards personalized intervention for Alzheimer\u2019s disease. Genomics Proteomics Bioinformatics 14(5):289\u2013297","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"1","key":"1781_CR254","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1073\/pnas.1111232108","volume":"109","author":"JM Perchiacca","year":"2012","unstructured":"Perchiacca JM, Ladiwala ARA, Bhattacharya M, Tessier PM (2012) Structure-based design of conformation- and sequence-specific antibodies against amyloid \u03b2. Proc Natl Acad Sci U S A 109(1):84\u201389","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"26","key":"1781_CR255","doi-asserted-by":"publisher","first-page":"16742","DOI":"10.1073\/pnas.262663499","volume":"99","author":"AT Petkova","year":"2002","unstructured":"Petkova AT, Ishii Y, Balbach JJ, Antzutkin ON, Leapman RD, Delaglio F, Tycko R (2002) A structural model for Alzheimer\u2019s \u03b2-amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S A 99(26):16742\u201316747","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1781_CR256","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3233\/JAD-180772","volume":"66","author":"R Pluta","year":"2018","unstructured":"Pluta R, U\u0142amek-Kozio\u0142 M, Januszewski S, Czuczwar SJ (2018) Tau protein dysfunction after brain ischemia. J Alzheimers Dis 66(2):429\u2013437","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"1781_CR257","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3233\/JAD-240058","volume":"98","author":"B Polis","year":"2024","unstructured":"Polis B, Samson AO (2024) Addressing the discrepancies between animal models and human Alzheimer\u2019s disease pathology: implications for translational research. J Alzheimers Dis 98(4):1199\u20131218","journal-title":"J Alzheimers Dis"},{"key":"1781_CR258","doi-asserted-by":"crossref","unstructured":"Prajapati C, Tripathi PN, Sood S, Rai SN, Mishra SS, Singh SK, Tiwari AK (2025) Intellectual property rights in neuroprotective biomaterials. Biomaterials and Neurodegenerative Disorders. Springer Nature Singapore, Singapore, pp 251\u2013269","DOI":"10.1007\/978-981-97-9959-6_10"},{"key":"1781_CR259","first-page":"413808","volume":"1","author":"A Prasansuklab","year":"2013","unstructured":"Prasansuklab A (2013) Tencomnao T (2013) Amyloidosis in Alzheimer\u2019s disease: the toxicity of amyloid beta (A\u03b2), mechanisms of its accumulation and implications of medicinal plants for therapy. Evid-Based Complement Alternat Med 1:413808","journal-title":"Evid-Based Complement Alternat Med"},{"issue":"3","key":"1781_CR260","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40263-024-01067-2","volume":"38","author":"Y Qiao","year":"2024","unstructured":"Qiao Y, Gu J, Yu M, Chi Y, Ma Y (2024) Comparative efficacy and safety of monoclonal antibodies for cognitive decline in patients with Alzheimer\u2019s disease: a systematic review and network meta-analysis. CNS Drugs 38(3):169\u2013192","journal-title":"CNS Drugs"},{"key":"1781_CR261","doi-asserted-by":"crossref","unstructured":"Ramakrishna K, Viswanadh MK, Dumala N, Chakravarth G, Venkateswarlu K, Gutti G, Yadagiri G, Duguluri S, Rai SN (2025) Advanced biomaterials in neuroprotection: innovations and clinical applications. In: Biomaterials and Neurodegenerative Disorders. Singapore, Springer Nature Singapore, pp 69\u201392","DOI":"10.1007\/978-981-97-9959-6_4"},{"issue":"32","key":"1781_CR262","doi-asserted-by":"publisher","first-page":"16517","DOI":"10.1039\/C3RA47754A","volume":"4","author":"K Ramaswamy","year":"2014","unstructured":"Ramaswamy K, Kumaraswamy P, Sethuraman S, Krishnan UM (2014) Self-assembly characteristics of a structural analogue of Tjernberg peptide. RSC Adv 4(32):16517\u201316523","journal-title":"RSC Adv"},{"key":"1781_CR263","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2164-14-382","volume":"14","author":"HR Ramey","year":"2013","unstructured":"Ramey HR, Decker JE, McKay SD, Rolf MM, Schnabel RD, Taylor JF (2013) Detection of selective sweeps in cattle using genome-wide SNP data. BMC Genomics 14:1\u201318","journal-title":"BMC Genomics"},{"issue":"16","key":"1781_CR264","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1091\/mbc.e12-12-0858","volume":"24","author":"EM Ramser","year":"2013","unstructured":"Ramser EM, Gan KJ, Decker H, Fan EY, Suzuki MM, Ferreira ST, Silverman MA (2013) Amyloid-\u03b2 oligomers induce tau-independent disruption of BDNF axonal transport via calcineurin activation in cultured hippocampal neurons. Mol Biol Cell 24(16):2494\u20132505","journal-title":"Mol Biol Cell"},{"issue":"3","key":"1781_CR265","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.neurobiolaging.2005.03.016","volume":"27","author":"MA Reger","year":"2006","unstructured":"Reger MA, Watson GS, Frey Ii WH, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27(3):451\u2013458","journal-title":"Neurobiol Aging"},{"key":"1781_CR266","doi-asserted-by":"crossref","unstructured":"Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey II WH, et al (2008) Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis13:323\u2013331","DOI":"10.3233\/JAD-2008-13309"},{"issue":"2","key":"1781_CR267","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/molecules23020283","volume":"23","author":"S Ribari\u010d","year":"2018","unstructured":"Ribari\u010d S (2018) Peptides as potential therapeutics for Alzheimer\u2019s disease. Molecules 23(2):283","journal-title":"Molecules"},{"issue":"6423","key":"1781_CR268","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao4827","volume":"363","author":"HC Rice","year":"2019","unstructured":"Rice HC, De Malmazet D, Schreurs A, Frere S, Van Molle I, Volkov AN, Creemers E, Vertkin I, Nys J, Ranaivoson FM, Comoletti D (2019) Secreted amyloid-\u03b2 precursor protein functions as a GABABR1a ligand to modulate synaptic transmission. Science 363(6423):eaao4827","journal-title":"Science"},{"issue":"1","key":"1781_CR269","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/biom13010169","volume":"13","author":"I Righetto","year":"2023","unstructured":"Righetto I, Gasparotto M, Casalino L, Vacca M, Filippini F (2023) Exogenous players in mitochondria-related CNS disorders: viral pathogens and unbalanced microbiota in the gut-brain axis. Biomolecules 13(1):169","journal-title":"Biomolecules"},{"issue":"12","key":"1781_CR270","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","volume":"60","author":"CW Ritchie","year":"2003","unstructured":"Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting A\u03b2 amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60(12):1685\u20131691","journal-title":"Arch Neurol"},{"key":"1781_CR271","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100402","volume":"296","author":"JP Roberts","year":"2021","unstructured":"Roberts JP, Stokoe SA, Sathler MF, Nichols RA, Kim S (2021) Selective coactivation of \u03b17- and \u03b14\u03b22-nicotinic acetylcholine receptors reverses beta-amyloid\u2013induced synaptic dysfunction. J Biol Chem 296:100123","journal-title":"J Biol Chem"},{"issue":"11","key":"1781_CR272","first-page":"1558","volume":"35","author":"EI Rogaev","year":"1999","unstructured":"Rogaev EI (1999) Genetic factors and a polygenic model of Alzheimer\u2019s disease. Genetika 35(11):1558\u20131571","journal-title":"Genetika"},{"issue":"1","key":"1781_CR273","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev.med.47.1.387","volume":"47","author":"MDAD Roses","year":"1996","unstructured":"Roses MDAD (1996) Apolipoprotein E alleles as risk factors in Alzheimer\u2019s disease. Annu Rev Med 47(1):387\u2013400","journal-title":"Annu Rev Med"},{"issue":"9","key":"1781_CR274","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1021\/acs.bioconjchem.4c00325","volume":"35","author":"RC Sabatelle","year":"2024","unstructured":"Sabatelle RC, Geller A, Li S, Van Heest A, Sachdeva UM, Bressler E, Korunes-Miller J, Tfayli B, Tal-Mason A, Kharroubi H, Colson YL (2024) Synthesis of amphiphilic amino poly-amido-saccharide and poly(lactic) acid block copolymers and fabrication of paclitaxel-loaded mucoadhesive nanoparticles. Bioconjug Chem 35(9):1429\u20131440","journal-title":"Bioconjug Chem"},{"key":"1781_CR275","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2020.108104","volume":"175","author":"LA Sandusky-Beltran","year":"2020","unstructured":"Sandusky-Beltran LA, Sigurdsson EM (2020) Tau immunotherapies: lessons learned, current status and future considerations. Neuropharmacology 175:108104","journal-title":"Neuropharmacology"},{"key":"1781_CR276","unstructured":"Saunders JC (2014) An in vivo platform for identifying protein aggregation inhibitors. PhD Thesis, University of Leeds"},{"issue":"21","key":"1781_CR277","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1021\/jm00021a001","volume":"38","author":"DB Schenk","year":"1995","unstructured":"Schenk DB, Rydel RE, May P, Little S, Panetta J, Lieberburg I, Sinha S (1995) Therapeutic approaches related to amyloid-\u03b2 peptide and Alzheimer\u2019s disease. J Med Chem 38(21):4141\u20134154","journal-title":"J Med Chem"},{"issue":"8","key":"1781_CR278","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E (1996) Secreted amyloid \u03b2\u2013protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat Med 2(8):864\u2013870","journal-title":"Nat Med"},{"key":"1781_CR279","doi-asserted-by":"crossref","unstructured":"Sch\u00f6ll M, Lockhart SN, Schonhaut DR, O\u2019Neil JP, Janabi M, Ossenkoppele R, Baker SL, Vogel JW, Faria J, Schwimmer HD, Rabinovici GD. (2016) PET imaging of tau deposition. Neuron 89(5):971\u2013982.","DOI":"10.1016\/j.neuron.2016.01.028"},{"key":"1781_CR280","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-024-02824-9","volume":"148","author":"S Schrempel","year":"2024","unstructured":"Schrempel S, Kottwitz AK, Piechotta A, Gnoth K, B\u00fcschgens L, Hartlage-R\u00fcbsamen M, Morawski M, Schenk M, Kleinschmidt M et al (2024) Identification of isoAsp7-A\u03b2 as a major A\u03b2 variant in Alzheimer\u2019s disease, dementia with Lewy bodies and vascular dementia. Acta Neuropathol 148:1\u201326","journal-title":"Acta Neuropathol"},{"issue":"3","key":"1781_CR281","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1039\/D4MD00729H","volume":"16","author":"N Sehra","year":"2025","unstructured":"Sehra N, Parmar R, Jain R (2025) Peptide-based amyloid-beta aggregation inhibitors. RSC Med Chem 16(3):1083\u20131104","journal-title":"RSC Med Chem"},{"issue":"2","key":"1781_CR282","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0896-6273(01)00475-5","volume":"32","author":"DJ Selkoe","year":"2001","unstructured":"Selkoe DJ (2001) Clearing the brain\u2019s amyloid cobwebs. Neuron 32(2):177\u2013180","journal-title":"Neuron"},{"issue":"6","key":"1781_CR283","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 8(6):595\u2013608","journal-title":"EMBO Mol Med"},{"key":"1781_CR284","unstructured":"Ser\u00e3o NV, Combarros O, Cortina-Borja M (2013) APOE genotype and Alzheimer risk. Alzheimers Dement 9(4):e67\u2013e74."},{"issue":"3","key":"1781_CR285","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","volume":"35","author":"L Seren\u00f3","year":"2009","unstructured":"Seren\u00f3 L, Coma M, Rodriguez M, S\u00e1nchez-Ferrer P, S\u00e1nchez MB, Gich I, Agull\u00f3 JM, P\u00e9rez M, Avila J, Guardia-Laguarta C, Clarim\u00f3n J (2009) A novel GSK-3\u03b2 inhibitor reduces Alzheimer\u2019s pathology and rescues neuronal loss in vivo. Neurobiol Dis 35(3):359\u2013367","journal-title":"Neurobiol Dis"},{"key":"1781_CR286","doi-asserted-by":"crossref","unstructured":"Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM. (2008) Amyloid-\u03b2 protein dimers isolated from Alzheimer\u2019s brains impair synaptic plasticity. Nat Med 14(8):837\u2013842.","DOI":"10.1038\/nm1782"},{"issue":"13","key":"1781_CR287","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1016\/j.febslet.2013.05.026","volume":"587","author":"SA Shariati","year":"2013","unstructured":"Shariati SA, De Strooper B (2013) Redundancy and divergence in the amyloid precursor protein family. FEBS Lett 587(13):2036\u20132045","journal-title":"FEBS Lett"},{"key":"1781_CR288","unstructured":"Shi Y, Holtzman DM (2020) Interplay between innate immunity and Alzheimer disease. Nat Immunol 21(6):687\u2013698."},{"key":"1781_CR289","doi-asserted-by":"crossref","unstructured":"Singh S, Rai SN, Singh SK (eds) (2024) Synaptic plasticity in neurodegenerative disorders. CRC Press","DOI":"10.1201\/9781003464648"},{"issue":"6","key":"1781_CR290","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jmgm.2005.08.002","volume":"24","author":"RD Smith","year":"2006","unstructured":"Smith RD, Hu L, Falkner JA, Benson ML, Nerothin JP, Carlson HA (2006) Exploring protein\u2013ligand recognition with binding MOAD. J Mol Graph Model 24(6):414\u2013425","journal-title":"J Mol Graph Model"},{"issue":"7","key":"1781_CR291","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nm0798-822","volume":"4","author":"C Soto","year":"1998","unstructured":"Soto C, Sigurdsson EM, Morelli L, Kumar RA, Casta\u00f1o EM, Frangione B (1998) \u0392-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer\u2019s therapy. Nat Med 4(7):822\u2013826. https:\/\/doi.org\/10.1038\/nm0798-822","journal-title":"Nat Med"},{"key":"1781_CR292","unstructured":"Soto C, Pritzkow S (2022) Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci 25(7):905\u2013919."},{"key":"1781_CR293","doi-asserted-by":"crossref","unstructured":"Sundaram DNM, Nasrullah M, Uludag H (2023) Cytokine response to nanoparticles bearing nucleic acid cargo. Advanced Drug Delivery: Methods and Applications. Springer Nature Singapore, Singapore, pp 229\u2013266","DOI":"10.1007\/978-981-99-6564-9_10"},{"issue":"5163","key":"1781_CR294","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1126\/science.8191290","volume":"264","author":"N Suzuki","year":"1994","unstructured":"Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos JL, Eckman C, Golde TE, Younkin SG (1994) An increased percentage of long amyloid \u03b2 protein secreted by familial amyloid \u03b2 protein precursor (\u03b2APP717) mutants. Science 264(5163):1336\u20131340","journal-title":"Science"},{"issue":"15","key":"1781_CR295","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1021\/bi100144m","volume":"49","author":"M Taylor","year":"2010","unstructured":"Taylor M, Moore S, Mayes J, Parkin E, Beeg M, Canovi M, Gobbi M, Mann DM, Allsop D (2010) Development of a proteolytically stable retro-inverso peptide inhibitor of \u03b2-amyloid oligomerization as a potential novel treatment for Alzheimer\u2019s disease. Biochemistry 49(15):3261\u20133272","journal-title":"Biochemistry"},{"key":"1781_CR296","doi-asserted-by":"crossref","unstructured":"Tcw J, Goate AM (2017) Genetics of \u03b2-amyloid precursor protein in Alzheimer\u2019s disease. Cold Spring Harb Perspect Med 7(6):a024539.","DOI":"10.1101\/cshperspect.a024539"},{"issue":"44","key":"1781_CR297","doi-asserted-by":"publisher","first-page":"29615","DOI":"10.1074\/jbc.R800019200","volume":"283","author":"G Thinakaran","year":"2008","unstructured":"Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283(44):29615\u201329619","journal-title":"J Biol Chem"},{"issue":"15","key":"1781_CR298","doi-asserted-by":"publisher","first-page":"8545","DOI":"10.1074\/jbc.271.15.8545","volume":"271","author":"LO Tjernberg","year":"1996","unstructured":"Tjernberg LO, N\u00e4slund J, Lindqvist F, Johansson J, Karlstr\u00f6m AR, Thyberg J, Terenius L, Nordstedt C (1996) Arrest of-amyloid fibril formation by a pentapeptide ligand (\u2217). J Biol Chem 271(15):8545\u20138548","journal-title":"J Biol Chem"},{"issue":"9","key":"1781_CR299","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26094271","volume":"26","author":"C Toader","year":"2025","unstructured":"Toader C, Serban M, Munteanu O, Covache-Busuioc RA, Enyedi M, Ciurea AV, Tataru CP (2025) From synaptic plasticity to neurodegeneration: BDNF as a transformative target in medicine. Int J Mol Sci 26(9):4271","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1781_CR300","first-page":"417","volume":"17","author":"K Tokuraku","year":"2011","unstructured":"Tokuraku K et al (2011) Peptide inhibitors of amyloid aggregation: from rational design to clinical development. J Pept Sci 17(6):417\u2013429","journal-title":"J Pept Sci"},{"issue":"3","key":"1781_CR301","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004568","volume":"22","author":"R Tonegawa-Kuji","year":"2025","unstructured":"Tonegawa-Kuji R, Hou Y, Hu B, Lorincz-Comi N, Pieper AA, Tousi B, Leverenz JB, Cheng F (2025) Efficacy and safety of passive immunotherapies targeting amyloid beta in Alzheimer\u2019s disease: a systematic review and meta-analysis. PLoS Med 22(3):e1004568","journal-title":"PLoS Med"},{"key":"1781_CR302","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2013.00079","volume":"4","author":"PP Tsitsopoulos","year":"2013","unstructured":"Tsitsopoulos PP, Marklund N (2013) Amyloid-\u03b2 peptides and tau protein as biomarkers in cerebrospinal and interstitial fluid following traumatic brain injury: a review of experimental and clinical studies. Front Neurol 4:39697","journal-title":"Front Neurol"},{"key":"1781_CR303","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3233\/JAD-150031","volume":"46","author":"PO Tsvetkov","year":"2015","unstructured":"Tsvetkov PO, Cheglakov IB, Ovsepyan AA, Mediannikov OY, Morozov AO, Telegin GB, Kozin SA (2015) Peripherally applied synthetic tetrapeptides HAEE and RADD slow down the development of cerebral \u03b2-amyloidosis in A\u03b2PP\/PS1 transgenic mice. J Alzheimers Dis 46:849\u2013853","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"1781_CR304","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/neurolint17060092","volume":"17","author":"E Twiss","year":"2025","unstructured":"Twiss E, McPherson C, Weaver DF (2025) Global diseases deserve global solutions: Alzheimer\u2019s disease. Neurol Int 17(6):92","journal-title":"Neurol Int"},{"key":"1781_CR305","unstructured":"Uddin MS, Kabir MT, Rahman MM, et al. (2020) Emerging promise of peptide-based therapeutics in Alzheimer\u2019s disease. Neurochem Int 162:105430."},{"key":"1781_CR354","doi-asserted-by":"crossref","unstructured":"Uddin KMM, Alam MJ, Jannat-E-Anawar, Uddin MA, Aryal S (2023) A Novel Approach Utilizing Machine Learning for the Early Diagnosis of Alzheimer's Disease. Biomed Mater Devices. 1\u201317","DOI":"10.1007\/s44174-023-00078-9"},{"issue":"3","key":"1781_CR307","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21030892","volume":"21","author":"M U\u0142amek-Kozio\u0142","year":"2020","unstructured":"U\u0142amek-Kozio\u0142 M, Czuczwar SJ, Januszewski S, Pluta R (2020) Proteomic and genomic changes in tau protein, which are associated with Alzheimer\u2019s disease after ischemia-reperfusion brain injury. Int J Mol Sci 21(3):892","journal-title":"Int J Mol Sci"},{"key":"1781_CR308","doi-asserted-by":"crossref","unstructured":"Ulland TK, Colonna M (2018) TREM2 a key player in microglial biology. Nat Rev Immunol 18(7):447\u2013459.","DOI":"10.1038\/s41582-018-0072-1"},{"issue":"5","key":"1781_CR309","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0301-0082(91)90015-S","volume":"36","author":"JW Unger","year":"1991","unstructured":"Unger JW, Livingston JN, Moss AM (1991) Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol 36(5):343\u2013362","journal-title":"Prog Neurobiol"},{"issue":"22","key":"1781_CR310","doi-asserted-by":"publisher","first-page":"13990","DOI":"10.1073\/pnas.222433299","volume":"99","author":"B Urbanc","year":"2002","unstructured":"Urbanc B, Cruz L, Le R, Sanders J, Ashe KH, Duff K, Stanley HE, Irizarry MC, Hyman BT (2002) Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer\u2019s disease. Proc Natl Acad Sci U S A 99(22):13990\u201313995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1781_CR311","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104852","volume":"141","author":"M Vasefi","year":"2020","unstructured":"Vasefi M, Ghaboolian-Zare E, Abedelwahab H, Osu A (2020) Environmental toxins and Alzheimer\u2019s disease progression. Neurochem Int 141:104852","journal-title":"Neurochem Int"},{"issue":"s2","key":"1781_CR312","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JAD-2011-110218","volume":"24","author":"B Vincent","year":"2011","unstructured":"Vincent B, Govitrapong P (2011) Activation of the \u03b1-secretase processing of A\u03b2PP as a therapeutic approach in Alzheimer\u2019s disease. J Alzheimers Dis 24(s2):75\u201394","journal-title":"J Alzheimers Dis"},{"key":"1781_CR313","doi-asserted-by":"crossref","unstructured":"Vlad SC, Miller DR, Kowall NW, Felson DT (2008) Protective effects of NSAIDs in Alzheimer\u2019s disease. Neurology 70(19):1672\u20131677.","DOI":"10.1212\/01.wnl.0000311269.57716.63"},{"issue":"1\u20132","key":"1781_CR314","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","volume":"15","author":"P Vlieghe","year":"2010","unstructured":"Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M (2010) Synthetic therapeutic peptides: science and market. Drug Discov Today 15(1\u20132):40\u201356","journal-title":"Drug Discov Today"},{"issue":"34","key":"1781_CR315","first-page":"E4976","volume":"113","author":"MA W\u00e4lti","year":"2006","unstructured":"W\u00e4lti MA, Ravotti F, Arai H, Glabe CG, Wall JS, B\u00f6ckmann A, G\u00fcntert P, Meier BH, Riek R (2006) Atomic-resolution structure of a disease-relevant A\u03b2 (1\u201342) amyloid fibril. Proc Natl Acad Sci U S A 113(34):E4976\u2013E4984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1781_CR316","doi-asserted-by":"crossref","unstructured":"W\u00e4lti MA, Ravotti F, Arai H, Glabe CG, Wall JS, B\u00f6ckmann A, G\u00fcntert P, Meier BH, Riek R. (2016) Atomic-resolution structure of amyloid \u03b2 fibrils. Proc Natl Acad Sci USA 113(34):E4976\u2013E4984..","DOI":"10.1073\/pnas.1600749113"},{"issue":"19\u201320","key":"1781_CR317","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.drudis.2006.08.004","volume":"11","author":"YJ Wang","year":"2006","unstructured":"Wang YJ, Zhou HD, Zhou XF (2006) Clearance of amyloid-beta in Alzheimer\u2019s disease: progress, problems and perspectives. Drug Discov Today 11(19\u201320):931\u2013938","journal-title":"Drug Discov Today"},{"issue":"8","key":"1781_CR318","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.2174\/13816128113199990068","volume":"20","author":"Q Wang","year":"2014","unstructured":"Wang Q, Yu X, Li L, Zheng J (2014) Inhibition of amyloid-\u03b2 aggregation in Alzheimer\u2019s disease. Curr Pharm Des 20(8):1223\u20131243","journal-title":"Curr Pharm Des"},{"key":"1781_CR319","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.695479","volume":"15","author":"D Wang","year":"2021","unstructured":"Wang D, Chen F, Han Z, Yin Z, Ge X, Lei P (2021) Relationship between amyloid-\u03b2 deposition and blood\u2013brain barrier dysfunction in Alzheimer\u2019s disease. Front Cell Neurosci 15:695479","journal-title":"Front Cell Neurosci"},{"key":"1781_CR320","unstructured":"Wang L, Gao F, Chen Z (2025) Targeted peptide therapeutics for amyloid clearance. Theranostics 15(3):1456\u20131472."},{"issue":"1","key":"1781_CR321","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00904-4","volume":"7","author":"L Wang","year":"2022","unstructured":"Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, Wang X, Wang R, Fu C (2022) Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther 7(1):48","journal-title":"Signal Transduct Target Ther"},{"issue":"17","key":"1781_CR322","doi-asserted-by":"publisher","first-page":"13110","DOI":"10.3390\/ijms241713110","volume":"24","author":"C Wang","year":"2023","unstructured":"Wang C, Shao S, Li N, Zhang Z, Zhang H, Liu B (2023) Advances in Alzheimer\u2019s disease-associated A\u03b2 therapy based on peptide. Int J Mol Sci 24(17):13110","journal-title":"Int J Mol Sci"},{"issue":"5869","key":"1781_CR323","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1126\/science.1151839","volume":"319","author":"C Wasmer","year":"2008","unstructured":"Wasmer C, Lange A, Van Melckebeke H, Siemer AB, Riek R, Meier BH (2008) Amyloid fibrils of the HET-s (218\u2013289) prion form a \u03b2 solenoid with a triangular hydrophobic core. Science 319(5869):1523\u20131526","journal-title":"Science"},{"issue":"12","key":"1781_CR324","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1212\/01.WNL.0000065916.25128.25","volume":"60","author":"GS Watson","year":"2003","unstructured":"Watson GS, Peskind ER, Asthana S, Purganan K, Wait C, Chapman D, Schwartz MW, Plymate S, Craft S (2003) Insulin increases CSF A\u03b242 levels in normal older adults. Neurology 60(12):1899\u20131903","journal-title":"Neurology"},{"issue":"1","key":"1781_CR325","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.neurobiolaging.2004.11.011","volume":"27","author":"GS Watson","year":"2006","unstructured":"Watson GS, Bernhardt T, Reger MA, Cholerton BA, Baker LD, Peskind ER, Asthana S, Plymate SR, Fr\u00f6lich L, Craft S (2006) Insulin effects on CSF norepinephrine and cognition in Alzheimer\u2019s disease. Neurobiol Aging 27(1):38\u201341","journal-title":"Neurobiol Aging"},{"issue":"7172","key":"1781_CR326","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/nature06526","volume":"450","author":"JA Wells","year":"2007","unstructured":"Wells JA, McClendon CL (2007) Reaching for high-hanging fruit in drug discovery at protein\u2013protein interfaces. Nature 450(7172):1001\u20131009","journal-title":"Nature"},{"issue":"3","key":"1781_CR327","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/13506120701460923","volume":"14","author":"P Westermark","year":"2007","unstructured":"Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda SI, Masters CL, Merlini G, Saraiva MJ, Sipe JD (2007) A primer of amyloid nomenclature. Amyloid 14(3):179\u2013183","journal-title":"Amyloid"},{"issue":"8","key":"1781_CR328","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/cbic.200300631","volume":"4","author":"K Wiesehan","year":"2003","unstructured":"Wiesehan K, Buder K, Linke RP, Patt S, Stoldt M, Unger E, Schmitt B, Bucci E, Willbold D (2003) Selection of D-amino-acid peptides that bind to Alzheimer\u2019s disease amyloid peptide A\u03b21\u201342 by mirror image phage display. ChemBioChem 4(8):748\u2013753","journal-title":"ChemBioChem"},{"issue":"20","key":"1781_CR329","doi-asserted-by":"publisher","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","volume":"93","author":"CM Wischik","year":"1996","unstructured":"Wischik CM, Edwards PC, Lai RY, Roth M, Harrington C (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 93(20):11213\u201311218","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1781_CR330","unstructured":"Wischik CM, Harrington CR, Storey JM. (2014) Tau aggregation inhibitor therapy. Alzheimers Dement 10(3 Suppl):S95\u2013S103."},{"key":"1781_CR331","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/B978-0-12-394816-8.00004-0","volume":"64","author":"MS Wolfe","year":"2012","unstructured":"Wolfe MS (2012) \u03b3-secretase as a target for Alzheimer\u2019s disease. Adv Pharmacol 64:127\u2013153","journal-title":"Adv Pharmacol"},{"issue":"3","key":"1781_CR332","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1021\/bi00003a003","volume":"34","author":"SJ Wood","year":"1995","unstructured":"Wood SJ, Wetzel R, Martin JD, Hurle MR (1995) Prolines and aamyloidogenicity in fragments of the Alzheimer\u2019s peptide. beta.\/A4. Biochemistry 34(3):724\u2013730","journal-title":"Biochemistry"},{"key":"1781_CR333","unstructured":"Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease. Annu Rev Pathol 7:303\u2013323."},{"issue":"10","key":"1781_CR334","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1021\/acsami.5b00915","volume":"7","author":"N Xiong","year":"2015","unstructured":"Xiong N, Dong XY, Zheng J, Liu FF, Sun Y (2015) Design of LVFFARK and LVFFARK-functionalized nanoparticles for inhibiting amyloid \u03b2-protein fibrillation and cytotoxicity. ACS Appl Mater Interfaces 7(10):5650\u20135662","journal-title":"ACS Appl Mater Interfaces"},{"issue":"2","key":"1781_CR335","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/13506120701260059","volume":"14","author":"S Xu","year":"2007","unstructured":"Xu S (2007) Aggregation drives \u201cmisfolding\u201d in protein amyloid fiber formation. Amyloid 14(2):119\u2013131","journal-title":"Amyloid"},{"issue":"39","key":"1781_CR336","doi-asserted-by":"publisher","first-page":"10378","DOI":"10.1002\/anie.201302840","volume":"52","author":"LM Yan","year":"2013","unstructured":"Yan LM, Velkova A, Tatarek-Nossol M, Rammes G, Sibaev A, Andreetto E, Kracklauer M, Bakou M, Malideli E, G\u00f6ke B, Schirra J (2013) Selectively n-methylated soluble IAPP mimics as potent IAPP receptor agonists and nanomolar inhibitors of cytotoxic self-assembly of both IAPP and A\u03b240. Angew Chem Int Ed 52(39):10378\u201310383","journal-title":"Angew Chem Int Ed"},{"key":"1781_CR337","unstructured":"Yanamandra K, Kfoury N, Jiang H (2013) Anti-tau antibodies block tau propagation. J Neurosci 33(13):5304\u20135312."},{"issue":"12","key":"1781_CR338","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1021\/jp0570420","volume":"110","author":"M Yang","year":"2006","unstructured":"Yang M, Lei M, Yordanov B, Huo S (2006) Peptide plane can flip in two opposite directions: implication in amyloid formation of transthyretin. J Phys Chem B 110(12):5829\u20135833","journal-title":"J Phys Chem B"},{"key":"1781_CR339","unstructured":"Yu YJ, Watts RJ (2023) Developing therapeutic antibodies for brain diseases. Nat Rev Drug Discov 12(2):137\u2013152."},{"key":"1781_CR340","unstructured":"Yang T, Li S, Xu H, Walsh DM, Selkoe DJ (2012) Large soluble oligomers of amyloid \u03b2-protein. Proc Natl Acad Sci USA 109(19):724\u2013729."},{"key":"1781_CR341","doi-asserted-by":"crossref","unstructured":"Xiao D, Zhang C. Current therapeutics for Alzheimer\u2019s disease and clinical trials. Explor Neurosci. 2024;3:255\u201371","DOI":"10.37349\/en.2024.00048"},{"key":"1781_CR342","doi-asserted-by":"crossref","unstructured":"Xiao Y, Wei L, Su J, Lei H, Sun F, Li M, Li S, Wang X, Zheng J, Wang JZ. A tau dephosphorylation-targeting chimeraselectively recruits protein phosphatase-1 to ameliorate Alzheimer's disease and tauopathies. Cell Chem Biol. 2024 Oct 17;31(10):1787-1799.e6","DOI":"10.1016\/j.chembiol.2024.09.003"},{"key":"1781_CR343","unstructured":"Zannad F(2021) Cardiovascular risk and dementia. Eur Heart J 42(8):742\u2013753."},{"key":"1781_CR344","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bpc.2018.02.002","volume":"235","author":"H Zhang","year":"2018","unstructured":"Zhang H, Dong X, Liu F, Zheng J, Sun Y (2018a) Ac-LVFFARK-NH2 conjugation to \u03b2-cyclodextrin exhibits significantly enhanced performance on inhibiting amyloid \u03b2-protein fibrillogenesis and cytotoxicity. Biophys Chem 235:40\u201347","journal-title":"Biophys Chem"},{"issue":"6","key":"1781_CR345","doi-asserted-by":"publisher","DOI":"10.1002\/jmr.2697","volume":"31","author":"H Zhang","year":"2018","unstructured":"Zhang H, Zhang C, Dong XY, Zheng J, Sun Y (2018b) Design of nonapeptide LVFFARKHH: a bifunctional agent against Cu2+-mediated amyloid \u03b2-protein aggregation and cytotoxicity. J Mol Recognit 31(6):e2697","journal-title":"J Mol Recognit"},{"key":"1781_CR346","doi-asserted-by":"crossref","unstructured":"Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards MS, Li G, Duncan JA. (2013) Purification and characterization of human astrocytes. Neuron 89(1):37\u201353.","DOI":"10.1016\/j.neuron.2015.11.013"},{"key":"1781_CR347","unstructured":"Zhao WQ, Alkon DL (1991) Role of insulin and insulin receptor in learning and memory. Mol Neurobiol 5(4):403\u2013418."},{"issue":"1\u20132","key":"1781_CR348","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0303-7207(01)00455-5","volume":"177","author":"WQ Zhao","year":"2001","unstructured":"Zhao WQ, Alkon DL (2001) Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 177(1\u20132):125\u2013134","journal-title":"Mol Cell Endocrinol"},{"issue":"1\u20133","key":"1781_CR349","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejphar.2004.02.045","volume":"490","author":"WQ Zhao","year":"2004","unstructured":"Zhao WQ, Chen H, Quon MJ, Alkon DL (2004) Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 490(1\u20133):71\u201381","journal-title":"Eur J Pharmacol"},{"key":"1781_CR350","unstructured":"Zheng H, Koo EH (2009) The amyloid precursor protein: beyond amyloid. Mol Neurodegener 4:34."},{"key":"1781_CR351","unstructured":"Zheng W, Liu Y, Zhou X (2025) Peptide modulators of neuroinflammation in Alzheimer\u2019s disease. Brain Behav Immun 115:210\u2013222."},{"key":"1781_CR352","doi-asserted-by":"publisher","unstructured":"Zheng WH, Kar S, Dore S, Quirion R (2000) Insulin-like growth factor-1 (IGF-1): a neuroprotective trophic factor acting via the Akt kinase pathway. Adv Res Neurodegener 261\u201372. https:\/\/doi.org\/10.1007\/978-3-7091-6301-6_17","DOI":"10.1007\/978-3-7091-6301-6_17"},{"issue":"3","key":"1781_CR353","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3233\/JAD-170062","volume":"58","author":"JB Zhu","year":"2017","unstructured":"Zhu JB, Tan CC, Tan L, Yu JT (2017) State of play in Alzheimer\u2019s disease genetics. J Alzheimers Dis 58(3):631\u2013659","journal-title":"J Alzheimers Dis"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-025-01781-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11011-025-01781-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-025-01781-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:03:27Z","timestamp":1775552607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11011-025-01781-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":349,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1781"],"URL":"https:\/\/doi.org\/10.1007\/s11011-025-01781-w","relation":{},"ISSN":["1573-7365"],"issn-type":[{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"30 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"78"}}